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Abstract 
The overall aim of this thesis is to investigate the combination of supramolecular cylinders with 
DNA nanotechnology and assess any effects that can occur through binding and any 
applications this could have in biomedical therapy applications. From this base it is hoped that 
insight can be gained as to whether supramolecular chemistry can be used to create DNA nano-
machines, capable of triggered release of cargo.  
The thesis begins with a review of DNA discovery, structure and binding by small molecules, 
followed by a review of the field of DNA nanotechnology. By expanding on the field of DNA 
nanotechnology recognition, chapters 2 and 3 will highlight the advantages of supramolecular 
chemistry when combined with DNA nanotechnology in both nano-machines and inside cell 
systems with a focus on DNA tetrahedral nanostructures. Chapter 4 researches the 
photocleavage capabilities of a ruthenium cylinder and the possibilities of selective release and 
photodynamic therapy using a DNA tetrahedron. Chapter 5 illustrates a new class of anti-viral 
agents capable of structure recognition regardless of RNA sequence. The chapter focuses on 
the inhibition of binding between the TAR RNA and ADP-1 peptide found in the HIV-1 virus. 
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Chapter 1  
 
Introduction 
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1.1 DNA – An Introduction 
1.1.1 Discovery of DNA 
DNA was first isolated by Friedrich Miescher in 1869. The Swiss chemist discovered what he 
called nuclein inside human white blood cells obtained from pus-coated bandages. By 
separating this phosphorus rich nuclein from the surrounding proteins, he realised he had 
discovered a new substance which started the track towards understanding DNA fully.1  
Following on from this initial discovery many years later in 1919 Phoebus Levene, a Russian 
biochemist put forward his polynucleotide theory, discovered through analysing hydrolysis 
products of nucleic acids. He stated that nucleic acids were in fact long chains of nucleotides, 
which turned out to be correct.2 Although the theory stated that nucleotides were long 
identical repeats of the nucleotides, the idea however, aided further research.3 
In 1950, a vital stepping stone was reported by Erwin Chargaff, he found from separating 
DNA samples with paper chromatography, the ratios of nucleic acids were different 
depending on the sample being analysed.4 From this he concluded that Phoebus Levene 
cannot be correct and that DNA has varying sequences. He also found that the ratio between 
the purines and the pyrimidines was 1:1 regardless of the sample source. Specifically he found 
that adenine and thymine were in equal proportions and the same was true of guanine and 
cytosine.4 This became known as ‘Chargaff’s rules’ and was instrumental in the eventual final 
elucidation of the structure of DNA.5 
Following from this, two English chemists, Rosalind Franklin and Raymond Gosling 
managed to produce the X-ray diffraction pattern of DNA in 1953 (Figure 1.1).6 This X 
structure shown in the picture suggested that the structure of DNA must be a repeating 
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structure which is uniform in nature. The crystallography also gave measurements for the 
width of DNA and therefore distances between the bases which would prove vital in 
discovering the final structure. Finally, with these initial pieces of evidence in place, Watson 
and Crick were able to propose their model of DNA in 1953.7 They proposed a right-handed 
double helical structure, with the nucleotide bases hydrogen bonded down the centre, 
surrounded by the phosphate-sugar backbone on the outside. Chargaff’s rule were also 
followed by correctly pairing A to T and G to C, resulting in the observed ratios of 1:1 
between the bases. Figure 1.2 shows the structure of DNA proposed by Watson and Crick in 
1953. 
 
Figure 1.1 - X-ray diffraction pattern of DNA produced by Franklin and Gosling. 
Taken from 6. 
Figure 1.2 – Original model of Watson and Cricks structure of DNA. Photo from the 
Archives at Cold Spring Harbor Laboratory.  
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1.1.2 Different Structures of DNA 
1.1.2.1 Helical DNA 
DNA has a huge variety of structures, but they mainly follow what is known as Watson-Crick 
base-pairing. As discussed earlier, this is the pairing between A and T and between G and C. 
This pairing is composed of hydrogen bonds between NH groups on one base and oxygen on 
an adjacent base. Figure 1.3 illustrates this hydrogen bond pairing between these bases.8 
 
 
 
  
 
 
The main form of helical DNA is known as B-DNA. Here, the bases shown above are bound 
to a deoxyribose unit to form what is known as a nucleotide. These nucleotides are then linked 
by a phosphate group to form long strands of nucleotides called an oligonucleotide. Two 
complimentary strands (with regard to the above Watson-Crick base pairing) are hydrogen 
bonded together as illustrated, with each base pair in the chains stacked with one above and 
one below and stabilised further by favourable π interactions from the aromatic groups in the 
bases. The bases are centralised due to their hydrophobicity and the stacking results in a 
double helix structure. As the helix turns, a major groove and a minor groove is created, with 
one of each per full turn of B-DNA. This full turn occurs across about 10-11 base pairs of 
helix.9 In vivo this form of DNA is by far the most common, carrying the genetic information 
Figure 1.3 – Drawing illustrating Watson-Crick base pairing between DNA nucleotides. Taken 
From 8. 
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for organisms.   There is another form of right handed double helical DNA possible known as 
A-DNA. This generally occurs in dehydrated samples of DNA and is estimated to form when 
relative humidity drops below around 75%.10 This is because with less H2O molecules 
available, the ribose sugars bend in a different fashion, causing the base pairs to bend away 
from the helical axis by a 19o angle meaning the phosphate groups can bind less H2O 
molecules.10 A-DNA as a result is shorter and wider than the B form of DNA. Biologically, 
the A form is thought to exist as protection against bacterial dehydration.11 It has also been 
proposed that due to the shorter conformation compared to B-DNA, the transition to A-form 
can drive the mechanism for genome packing in bacteriophages.12 
The final form of helical DNA found in biology differs from the other two as it is left-handed, 
meaning the double helix winds to the left. The phosphate groups in the backbone zig-zag in 
an alternating fashion, hence coining the Z name.13 The helix is thinner and more elongated 
than in B-DNA with around 12 bp per turn and a diameter reduced from 2 nm to 1.8 nm. The 
major and minor grooves have little difference in size and the structure as a whole is 
considered to be unfavourable.14 It is rarely formed in vivo as it is higher energy than B DNA 
and is thought to form briefly due to biological activity such as during transcription to relieve 
torsional strain in supercoiled DNA.15 All three helical DNA forms are visually represented in 
figure 1.4. 
 
 
 
 
 
 Figure 1.4 – Left: A-DNA, Centre: B-DNA, Right: Z-DNA. Taken from 8. 
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1.1.2.2 DNA Junctions 
There are two types of DNA junctions that can form in vivo. The first is the three way 
junction (3WJ) of which the replication fork is one example. These occur as the name 
suggests during cell replication as the DNA is split and copied by enzymes such as DNA 
polymerase. Figure 1.5a shows the structure of a 3WJ, which consists of helical DNA which 
is then split into single strands which then form a template for complimentary bases to be 
added to each emerging single strand to produce two final helical pieces of DNA.16  
A Holliday junction (named after the discovering scientist Robin Holliday) is a DNA four 
way junction (4WJ) (figure 1.5b). It consists of four double stranded pieces of helical DNA 
joined together in one junction. These form in vivo in repair mechanisms and in biology the 
junction is not stationary and can slide up and down each strand by breaking and pairing bases 
as it moves.   
Both of these structures have been replicated in vitro with short synthetic oligonucleotides, 
resulting in further studies on their structure.17, 18 These structures are have been more 
recently utilised in the field of DNA nanotechnology as a means to build up structures 
comprised of DNA.19 This area will be covered in depth later on in the chapter.    
 
 
 
 
 
 
 
Figure 1.5 – A) Representation of a DNA 3WJ. B) Representation of a DNA 4WJ. 
Taken from 18. 
A                                            B 
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1.1.2.3 Guanine Quadruplex 
The guanine quadruplex (G4 DNA) is a DNA secondary structure which does not follow 
traditional Watson-Crick base pairing. Instead it exhibits ‘Hoogsteen’ binding between 4 
guanine molecules to form a G-quartet with a central metal cation such as sodium or 
potassium. (Figure 1.6a). Because of this, the structure can only form in guanine rich 
sequences. These G-quartets then stack upon one another through π-interactions to form a 
guanine quadruplex (figure 1.6b).20 21   
 
 
 
 
 
 
 
 
 
These structures are found at the end of the chromosomes and protect the ends of a subset of 
some genes during replication.20 They have also been found to have significant roles in 
biological systems, such as formation in the telomeric regions in cells to reduce the action of 
telomerase, which lengthens the telomeres and increases cell lifetime. Overexpression of 
telomerase can lead to immortalised cells which replicate indefinitely and as such is thought 
to be involved in around 80-85% of all types of cancer.22 The potential presence of G-
quadruplex structures has also been discovered in oncogene promotor regions.23 G-
quadruplexes of varying topologies, specific to mutated genes relating to a number of cancers, 
B A 
Figure 1.6 – A) G quartet exhibiting four guanine bases with Hoogsteen binding and 
stabilising central metal cation. B) Representation of stacking G quartets to form a G-
quadruplex. Taken from 21 
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have been reported such as human c-MYC24 and human c-KIT25 (figure 1.7)26. Formation of 
G-quadruplex in these genomic DNA sequences can alter protein output by blocking 
transcription mechanisms. As each of these quadruplex topologies vary, they have attracted 
great interest as targets for selective chemotherapy drugs, some of which will be explored 
later.  
 
1.1.3 Targeting DNA structures with small molecules 
DNA has long been a very attractive target for drug design as biological outputs start at the 
DNA level. This means that many diseases such as cancer have their roots in DNA changes 
and mutations. Alterations in the genetic code of a cell can lead to differing transcriptions of 
RNA which ultimately leads to altered expression of proteins or enzymes which leads to 
uncontrolled cell proliferation and function. An example of cancer being caused by changes in 
protein expression is the well-known simultaneous over expression of the proteins Bcl-2 (an 
anti-apoptic protein)27 and Myc (a gene expression regulator)28, which are characteristic in B-
cell lymphoma and cause uncontrollable cell proliferation.29 Targeting these DNA genes 
which causes these expressions could offer selective therapy for many cancers. Cancer isn’t 
Figure 1.7 – Left: G-quadruplex topology found in the promoter region of the c-MYC 
oncogene. Right: G-quadruplex topology found in the promoter region of the c-KIT 
oncogene. Taken from 26. 
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the only disease with interesting DNA targets which could have therapeutic effects; Viruses 
such as HIV work by integrating genetic material in the form of DNA or RNA into host cells. 
In the case of HIV this infection allows for virus proliferation and cell death in the host T-
lymphocytes, leading to loss of immune system for the patient.30  
This section aims to review the significant developments in drug and small molecule designs 
for targeting DNA for applications in the clinic, discussing and providing examples of the 
main modes of DNA binding exhibited by each.  
1.1.3.1 Cisplatin and Derivatives 
Cisplatin or cis-diamminedichloroplatinum(II) (Figure 1.8a) is a square planar Pt(II) 
compound with two chloride and two ammine ligands in a cis arrangement. As part of the 
alkylating agent drug family, the biological effects of cisplatin were first reported in 1965 by 
Rosenberg who noticed that cisplatin could inhibit proliferation of E.coli bacteria.31 Its anti-
cancer properties were then studied and in 1978 it became the first anti-cancer metallo-drug to 
become licensed.32 Since then it has been used to treat a huge range of cancers including 
bladder, testicular, cervical, head, neck, ovarian, small cell lung, germ cell cancers as well as 
sarcomas and lymphoma.33, 34  
Cisplatin’s action results from its DNA binding ability. Once in the cell, the chloride ligands 
are hydrolysed and the platinum is free to bind directly the N7 reactive centre on purine DNA 
bases (typically guanine). It binds directly to two adjacent purines and this interaction leads to 
DNA kinking which makes DNA replication impossible while the adduct remains in place 
(Figure 1.8b).35 The DNA damage activates various apoptotic factors which lead to cell 
apoptosis.36 The DNA binding is a metal-ligand bind and opened up research into thousands 
of other coordination and covalent DNA binders.36 This is important because cellular 
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mechanisms can develop to form resistance to cisplatin action. Many mechanisms have been 
identified and once cells have been exposed to cisplatin, they begin to develop. Some main 
examples of these are decreases in cellular uptake and increases in efflux to reduce overall 
accumulation37, increases in DNA repair proteins such as topoisomerase II which can remove 
cisplatin from the DNA adducts by double stranded excision to reform undamaged DNA.38 
 
It is also worth noting that cisplatin does not discriminate between cancerous cells and the 
patient’s healthy cells. This causes tissue damage throughout the body and significant side 
effects which create a narrow therapeutic window and limit its clinical use. Major side effects 
are neurotoxicity, nephrotoxicity, ototoxicity, haemolytic anaemia, cardiotoxicity and severe 
nausea.36 It is these side effects and resistance which inspired a generation of Pt(II) drugs 
which act in a similar fashion but have varying ligands to reduce toxicity and circumvent drug 
resistance. Figure 1.939 shows the structures and names of a range of cisplatin derivatives that 
have been developed and subsequently been licensed for use in the clinic. Briefly, carboplatin 
has been the most successful of these, gaining worldwide approval. Its replacement of the 
A B 
Figure 1.8 – A) Molecular structure of cisplatin. B) Three-dimensional illustration of 
a cisplatin-DNA adduct. Platinum shown as a white sphere with the two amine ligands 
as blue spheres. Taken from 35.  
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chloride ligands with one bidentate 1,1-cyclobutanedicarboxylic acid led to significantly 
reduced organ toxicity40, although the mechanism of action and the DNA lesion remains the 
same so cisplatin resistant cells are often also carboplatin resistant.41 Some progress has been 
achieved in overcoming resistance with other agents such as oxaliplatin which by replacing 
the amines (and thus changing the DNA lesion) has been shown to be effective against some 
cisplatin resistant cell lines.42 None of these, however, can specifically target certain cancers, 
but are an excellent example of the class of clinical “alkylating agents” with respect to DNA 
targeting and binding.    
  
1.1.3.2 Intercalators 
DNA intercalation is the insertion of planar small molecules in-between the spaces separating 
the DNA base pairs in the helix.43 For this to be possible, the drugs designed are usually 
Figure 1.9 – Cisplatin and its second generation derivatives. Taken from 39.  
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polycyclic, aromatic and therefore planar which allows the molecule to stack by π-interactions 
with the base pairs (Figure 1.10).44 Ionic interactions between the intercalator and the negative 
charge on the phosphate backbone are also key to adduct stabilisation. The planar 
characteristic means that the base pairs will not be pushed out of plane which would make 
binding energetically unfavourable. The intercalation does however, have an effect on the 
helix. A gap must be made to make space and so the base pairs in which the drug will 
intercalate lengthen by about 3.5Å per drug molecule.45 To account for this extra length, the 
turn of the helix must relax and therefore the DNA unwinds to some extent. Due to the strain 
on the helix, only 1 intercalator can fit per 2 nucleotide groups, this is known as the 
neighbouring pair effect. This unwinding is completely dependent on the intercalating 
molecule and the overall action of the drug will be based on this also. This is because the 
unwinding causes problems with the action of topoisomerases; enzymes responsible for 
unwinding the helix before the DNA can undergo transcription.45  
Figure 1.10 – Intercalation of a small molecule (in this case ethidium bromide), 
illustrating the gap formed between DNA bases and the lengthening of the phosphate 
backbone. Taken from 44. 
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It is proposed that as the mode of action of anti-cancer intercalators is to poison the action of 
topoisomerases, specifically topoisomerase II (TOP2), that these drugs can exhibit selectivity 
towards cancer cells as TOP2 is active during cell proliferation, which is much more abundant 
in tumours than in healthy tissue.46 There is much evidence for the action of the most 
successful anti-cancer intercalators to be based on enzyme based damage due to TOP2 
inactivation.47, 48 Anthracycline antitumor antibiotics, specifically doxorubicin and 
daunorubicin (figure 1.11) are a very important family of drugs discovered that intercalate 
into DNA, forming ionic bonds with the phosphate backbone through the protonated amino 
group on the sugar and inhibiting TOP2 activity.   
 
 
 
 
     
   
 
 
It is worth pointing out that the activities of these two drugs are quite different, as 
daunorubicin is only active against leukaemias whilst doxorubicin has a wide range of anti-
cancer activity due to the addition of one hydroxyl group. It is thought this is due to the 
differences of lipophilicity, with doxorubicin with lower lipophilicity able to form 
electrostatic interactions more readily in the cellular environment.49 Although it could also be 
Figure 1.11 – Chemical structure of doxorubicin (left) and daunorubicin (right). 
Difference between the two molecules highlighted by blue hydroxyl group on 
doxorubicin. Taken from 34 
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due to daunorubicin being less able to access solid tumours and therefore more suitable for 
blood cancers. Figure 1.12 illustrates a doxorubicin-DNA adduct.50 
 
1.1.3.3 DNA Groove Binders 
By exploiting the major and minor grooves in the DNA helix, it is possible to design small 
molecules to target these areas for therapeutic effect. The first to be considered are minor 
groove binders. These drugs are designed to possess certain key features that make them 
suitable for this type of binding. Short chains of heterocyclic or aromatic hydrocarbons with 
freedom of rotation are characteristic to allow them to stabilise the DNA structure in the 
minor groove through displacement of water from the hydration layer surrounding DNA 
through π-interactions.35 Another important feature usually included in design is cationic 
groups at the end of the heterocyclic/aromatic chains. These serve to form hydrogen bonds 
Figure 1.13 – Left) Chemical structure of DAPI. Right) DNA minor groove binding 
of DAPI. Taken from 52. 
Figure 1.12 – Structure of two doxorubicin molecules intercalated into a DNA helix. Taken 
from 50.  
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directly to the DNA bases as well as to interact electrostatically with the anionic phosphate 
backbone. All of these are an important factor in this form of DNA binding.51 They tend to 
have a binding preference for AT over GC rich sequences as these provide a smaller minor 
groove which offers better binding sites for the molecule.52 Figure 1.13 illustrates the binding 
of DAPI (4',6-diamidino-2-phenylindole), a minor groove binder commonly used in 
fluorescence microscopy as a stain for DNA.  
 In the clinic, many minor groove binders have been investigated as this type of binding can 
inhibit the activity of polymerases, providing useful biological activity which has been 
utilised in anti-parasitic, antibiotic and antiviral applications.53 One key example is that of 
distamycin (figure 1.19), a polyamide antibiotic containing many of the key features 
discussed earlier. This minor groove binder also has binding preference at AT rich regions. Its 
main action is through inhibiting DNA transcription.54 Many derivatives and combination 
treatments from this natural product have found use in anti-cancer therapy, acting as 
antineoplastic agents.55, 56 
 
The second form of groove binding targets the other groove structure in DNA, the major 
groove. This structure is much larger than the minor groove and also has great variety in 
Figure 1.14 – Chemical structure of distamycin. Taken from 56. 
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shape and binding sites due to differing base pair sequences. The interactions between the 
molecule and DNA are often specific hydrogen bonds directly to the DNA bases.52 Features 
characteristic of major groove binders are that firstly they are too bulky to bind to the minor 
groove. Molecules employing an alpha helical peptide structure that match the turn of the 
DNA are also characteristic. Strong examples of these are protein motifs such as a zinc finger 
which can form base pair specific hydrogen bonds to the bases and the cylindrical shape can 
fit perfectly into a major groove.52 This type of recognition is often found naturally in the 
body in protein mediated biological activity (Figure 1.15). By mimicking some of these 
established proteins, some success has been found in designing proteins that can recognise 
specific DNA sequences57, 58, but the complexity and unpredictability of the hydrogen 
bonding involved make it very difficult to design novel therapeutic peptides that target these 
structures.59  Success was also found by Hannon et al by synthesising a di-nuclear 
supramolecular iron helicate60, roughly the same size as a zinc finger and capable of binding 
inside a major groove. This helicate will be discussed in full later on in the chapter.  
Figure 1.15 – X-ray crystal structure of a zinc finger – DNA complex, the protein 
involved is a transcription protein derived from e.coli bacteria. Protein data bank 
number: PDT039. Taken from 57 
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By exploiting hydrogen bonding in similar, single stranded pieces of DNA or 
oligonucleotides are also able to bind to the major groove through Hoogsteen or reverse 
Hoogsteen base pairing on the exposed side of the purine bases. Both protonated cytosine and 
guanine can bind a guanine base and both adenine and thymine can bind an adenine through 
this fashion (figure 1.16).52 This binding is sequence specific to sections of purine bases and 
when bound, forms what is known as triplex DNA – 3 strands of DNA in the helix. This sort 
of binding has been found to interfere with gene expression and its sequence specific nature 
has attracted some research attention. Notably the drug Fomivirsen is an antiviral 
oligonucleotide with the sequence GCG TTT GCT CTT CTT CTT GCG (5’-3’). It blocks 
viral action by binding to viral mRNA, halting vital protein expression.61 
Figure 1.16 – A) Chemical structures of Hoogsteen base pairing in triplex DNA, B) 
Reverse Hoogsteen base pairing. Taken from 52 
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1.1.3.4 G-Quadruplex Binders 
As discussed earlier, G-quadruplexes form in guanine rich areas of the genome which have 
been found to have strong biological significance such as the telomeres and gene promotor 
regions of key oncogenes. They are also unusual DNA structures with strong characteristic 
features whose topologies vary widely. For these reasons, they have been a target of wide 
interest in recent years.62, 63 They are considered to be druggable due to their role in the 
majority of human cancers, whether it be inhibiting the action of telomerase which has a key 
role in cell immortalisation and transformation64 or in the gene promoter regions of key 
oncogenes such as c-MYC, controlling expression of proliferation enzymes.28 Hundreds of 
small molecules have been synthesised in recent years which have been shown to interact 
with G-quadruplexes with certain characteristic molecule designs becoming apparent.65 
Figure 1.17 shows some examples of proven G-quadruplex binding compounds that have 
Figure 1.17 – A) telomestatin, a known G-quadruplex binder and telomerase 
inhibitor. B) TMPyP4, a strong quadruplex binder with potent anti-cancer activity. 
Taken from 66.  
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made it to clinical trials. Both the molecules shown exhibit a large amount of planar aromatic 
groups for stacking on top of the upper or lower most G-tetrad in the quadruplex.66 Square 
planar complexes with central metal cations such as Pt(II) or Pd(II) have also been suggested 
as the metal ions help co-ordinate ligands in the square planar fashion required for stacking.67 
The positive central charge can also stabilise the quadruplex by substituting the central cation 
Na+ or K+ usually found inside the quadruplex.67  
 
1.1.3.5 Cylinder DNA binding 
The focus of this thesis will be a metallosupramolecular iron cylinder (FeCy) and its 
enantiomers, first designed and synthesised by Hannon et al in 1997 (figure 1.18b).60  
 
 
 
 
 
 
 
Figure 1.18 - A) top: Synthetic scheme of the reaction step to form the cylinder ligand. B) 3D 
diagram of the cylinder, each of the three ligands shown in red, blue and green with the two 
central iron ions as yellow spheres, bottom figure taken from 60. 
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Two other cylinders, containing Ni and Ru (NiCy and RuCy) as centres in place of iron will 
also be explored. The iron cylinder is so named due to its cylindrical 3D shape. It is roughly 2 
nm in length and 1 nm in width which gives it similar dimensions to that of a zinc finger 
protein which is able to bind major grooves in DNA. The FeCy compound is synthesised in a 
simple one pot reaction (Figure 1.18a)68. Firstly the pyridylimine ligand is formed before 
complexation of 3 equivalents of the ligand to 2 equivalents of FeCl2 to form the iron cylinder 
as a racemic mixture of two enantiomers. These two enantiomers exist due to the inherent 
helical structure of the ligands leading to either a left-handed helicate, known as the M 
enantiomer, or the right handed helicate, known as the P enantiomer (Figure 1.19a). These 
enantiomers were first separated in 2001 using filter paper as a cellulose chiral stationary 
phase.69 Since then, cellulose powder column protocols have been developed to allow easy 
and clear separation of the enantiomers (Figure 1.19b). The cylinder is tetracationic, which 
helps in its strong binding to DNA and a variety of counter ions are available to the structure, 
most notably Cl- which allows the cylinder to be water soluble and so very useful in 
biological experiments.   
 
  
 
 
   
 
 
Figure 1.19 – A) Left: Crystal structures of both the M (left) enantiomer and P (right) 
enantiomer. Taken from 69. B) Right: Cellulose column showing separation of 
enantiomers, eluting M enantiomer first followed by the P.  
   M                    P 
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The DNA binding activity of the cylinder has been studied in some depth. To begin with, the 
cylinder was shown to bind inside the major groove of DNA (Figure 1.20).70  
The high cationic charge of the cylinder allows binding of the polyanionic DNA and as such 
has a number of dramatic effects on the DNA. By binding across about 5 bp in the duplex, the 
cylinder causes the DNA to ‘wrap-up’ and coil intramolecularly which has been illustrated by 
AFM (Figure 1.21).70 As discussed earlier, major groove binding proteins tend to match the 
helical turn of B-DNA and this is also true of the cylinder. As it has two enantiomers, 
however, they have been shown to have different binding modes to DNA.71 The M 
enantiomer induces much more coiling in DNA than the P. Further experimentation here 
showed that while the M enantiomer can be proven to bind to the major groove, P enantiomer 
binding was found to be unlikely to be here, and the most likely binding area was bridging 2 
phosphate groups in the backbone across the minor groove. This is a less perfect fit and thus 
can explain the discrepancy in binding strength and coiling.71 
Figure 1.20 – Structures of confirming cylinder binding inside a DNA major groove 
synthetically formed in solution by the oligonucleotide [5′-d(GACGGCCGTC)]2. 
Resolved by NMR experiments. Figure taken from 70.  
22 
 
 
The iron cylinder has also been shown to bind another DNA structure which is unprecedented 
in small molecule DNA recognition. It can recognise, bind and stabilise a DNA three way 
junction (3WJ) (figure 1.22).72 3WJ structures, as discussed earlier, form in DNA strands 
during replication, where a topoisomerase unwinds the DNA and polymerase can start to 
duplicate the strand. With regards to cancer therapy, 3WJ are an attractive target as cancer 
cells proliferate at a much accelerated rate compared to a healthy cell and so will have a 
higher proportion of 3WJ and so could offer some form of drug selectivity. 
The cylinder has been shown to have a preference for 3WJ structures over B-DNA72. It is also 
possible that the cylinder will preferentially bind to other DNA structures, the degree of which 
will be explained and discussed further in Chapter 2. Interestingly, the crystal structure of the 
Figure 1.21 – AFM images of the linearised plasmid pBR322, 4361 bp, diameter of 
475 nm, cleaved with Pst I and Sal I enzymes to give two linear fragments of 1401 bp 
and 2962 bp. A) linear plasmid fragments alone, B) Low concentration of FeCy with 
plasmid, C) Medium concentration of FeCy with plasmid, D) High concentration of 
FeCy with plasmid. Taken from ref 70 
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cylinder binding inside the 3WJ in figure 1.22 universally showed the M enantiomer bound 
inside the 3WJ despite the fact the DNA was incubated with a racemic mixture.72 This result 
is not an exhaustive study of the enantiomer interactions with the 3WJ and cannot conclude 
that the P enantiomer does not bind. It does, however, suggest that the M enantiomer does 
bind more effectively than the P enantiomer.  
The binding of the cylinder also causes distortion, the result of which leads to bases stacking 
out of plane and the backbone bending.72 This is important biologically as it is less likely that 
enzymes will be able to initiate transcriptions when cylinder and thus gene protein expression 
can be altered.  
Figure 1.22 – A) ‘major groove’ side of the 3WJ with cylinder bound inside the 
centre. B) ‘minor groove’ side of the 3WJ with cylinder bound inside. C) Side on view 
of the cylinder bound 3WJ, showing the ligands on the major groove side sticks out 
further than the minor groove side. Taken from 72. 
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In this regard, the biological activity of the iron cylinder has been studied in some depth due 
to its unique and powerful DNA binding capabilities. Against cancer cells, the cylinder has 
been shown to have potent cytotoxicity against numerous cell lines whilst proving not to be 
genotoxic or mutagenic in comet assays or the AMES test.68 
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1.2 DNA Nanotechnology  
1.2.1 Origins and methods of structural DNA Nanotechnology 
The concept of DNA nanotechnology was first publicised by Professor Nadrian Seeman at 
New York University in 1982 73, where, taking inspiration from a repeating unit picture in a 
local pub, noticed similar interactions could be translated to synthetic ssDNA. By definition, 
DNA nanotechnology is a branch of nanotechnology concerned with the design, study and 
application of synthetic structures based on DNA. DNA nanotechnology takes advantage of 
the physical and chemical properties of DNA rather than the genetic information it carries. 
Specifically Seeman outlined that designed synthetic oligonucleotide strands could self-
assemble into predetermined DNA structures.73,74 This was based on maximising well known 
Watson-Crick base pairing interactions and minimising symmetry which would lead to linear 
duplexes of DNA. Seeman provided proof of this concept when he synthesised a 3D cube 
structure starting with specifically designed oligonucleotides.19 Figure 1.23 illustrates the 
scheme starting with cyclised ssDNA leading finally to the fully formed 3D cube over a 
multi-step synthesis. This initial bottom-up approach, whilst providing proof of concept for 
Seeman, proved to be a laborious synthesis which provided just a 1 % yield.  
The general synthetic approach for this bottom-up scheme begins with ssDNA.  These strands 
are designed specifically and synthetically made so they can hybridise to the most favourable 
Watson-Crick base pairing and give predictably positioned double stranded DNA.  To allow 
these oligonucleotides to cyclise with themselves or ligate end to end with other  
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oligonucleotides, they must first be phosphorylated.75 This is the process of attaching an ATP 
group to the 5’ or 3’ end of an oligonucleotide, generally using a kinase enzyme in the 
presence of ATP to facilitate the reaction. Once phosphorylated, the strands can be hybridised 
together to form duplex DNA strands. In Seeman’s synthetic scheme a process known as 
annealing is employed. This simple step involves heating the strands together in 
stoichiometric quantities in buffer beyond the DNA melting point at which all hydrogen 
bonds are dissociated. Once left to cool, the strands form hydrogen bonds together according 
to the most thermodynamically favourable Watson-Crick base pairing and form the pre-
meditated duplex structure desired. Ligase enzymes can then be used to ligate the additional 
ATP groups into the formed structure.  
Another key DNA nanotechnology method is also known as ‘sticky-ended cohesion’76 which 
is a key technique in all genetic microbiology and can be illustrated more clearly in figure 
1.24.77 Here, two complimentary ssDNA overlaps at the end of two pieces of helical DNA can 
be annealed together with great affinity. This is because the sequence specific affinity for each 
Figure 1.23 – Schematic diagram illustrating Prof. Seeman’ first synthesis of the 3D 
DNA cube. Taken from 19.  
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is known and will be highly specific as long as any competing species have altered 
overlapping sequences that provide less favourable hydrogen bonding. This concept is central 
to the majority of DNA nanostructures produced in the last 35 years which rely on sequence 
specific and sequential structural motifs.78 
 
 
 
 
 
 
As discussed early, branched junctions of DNA occur throughout the genomic DNA in the 
cell. To create small DNA structures, such as the cube, it is imperative that rigid and stable 
junctions can be assembled.73 In biology the strands involved in the earlier discussed three 
and four way junctions, have symmetry with each other. This allows junction migration which 
is key to the biological process as the strands move through the enzymes, which involves 
breaking and reforming the hydrogen bonds between each nucleotide as the junction moves 
down the duplex.79 However, in DNA nanostructures, junction migration is undesirable. To 
avoid this, junctions must be designed to minimise symmetry between all single strands 
involved in the junction.80 This is illustrated clearly in figure 1.25, which shows that by 
eliminating symmetry in the strands involved in the junction, only 1 stable form of junction is 
Figure 1.24 – Schematic diagram, illustrating the single stranded overhangs of the 
duplex DNA hydrogen bonding together to form a single duplex. Taken from 77. 
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synthesised and junction migration is impossible as there is no complimentary nucleotides for 
the boxed tetrad of nucleotides in the junction. This method works for junctions with few 
arms such as the Holliday junction, but more complicated and imaginative approaches have 
been developed to synthesise junctions with higher numbers of arms, as symmetry is difficult 
to eliminate here across the junction.81 
 
 
 
 
 
 
These basic methods form the basis of designing and synthesising a small DNA 
nanostructure. There are more methods and a whole other branch of DNA nanotechnology has 
developed known as DNA origami which will be discussed in depth later in the review. 
Figure 1.25 - Sequence model for a synthetic 4-way junction. The sequences are of 13 
overlapping tetramers. The first two are boxed at the top of the model. The second 
boxed tetramer (AGTC) illustrates there is no complimentary tetramer anywhere in the 
model to ensure no pairing across the junction. The boxed trimers (ATG) clearly could 
compete here but the free energy difference between the desired junction and the 
trimer prevents this. Taken from 81.  
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Before this, various examples of structures originating from these methods and their impacts 
will be discussed.  
1.2.2 Small 3D DNA structures 
By exploiting the design and construction techniques discussed above, numerous research 
groups have reported synthesis of a wide variety of small 3D DNA structures. Notable 
examples building on from Seeman’s initial cube, include a truncated octahedron82, reported 
by Zhang and Seeman in 1994. The structure, shown in figure 1.26 shows each vertex is 
separated by 2 helical DNA turns, this structure was a step up in terms of complexity from the 
cube, and like the cube, it was flexible due to all nicks in the duplex being ligated. The 
structures were never able to be resolved microscopically and so, gel electrophoresis had to be 
relied upon for structure elucidation. It is also worth noting that the synthesis involved many 
steps and purifications and thus, took around 2 years to complete start to finish and had a low 
yield of less than 1%.82  
 
 
 
 
 
 
Figure 1.26 – Proposed structure of a DNA octahedron. Taken from 82. 
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An advance was made on this labour intensive synthetic method by Shih et al in designing a 
truncated octahedron out of a 1.7 Kb strand which was designed to be folded into an 
octahedron by a simple annealing step.83 The structure was able to be resolved with cryo-
electron microscopy and provided some of the first microscopy images of small 3D DNA 
nanostructures. Figure 1.27 shows the microscopy images obtained here, interestingly AFM 
images were not reported in this publication and this could be due to the structures inherent 
flexibility, which wouldn’t allow the structure to resist the pressures involved in AFM 
analysis to provide images that would accurately reflect the overall structure.  
 
 
 
Figure 1.27 – A) Raw Cryo-EM images of Octahedron. B) Projections of expected 
image. C) Raw images of each expected orientation. Taken from 83. 
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1.2.2.1 DNA Tetrahedron  
A DNA tetrahedron structure reported in 2004 by Turberfield et al was a revolutionary single 
step self-assembled 3D DNA structure, synthesised at a yield of over 95%, depending on 
concentration.75 This structure attracted a lot of interest and many variants have been 
synthesised and the structure very well characterised.84 The tetrahedron is also a major focus 
in this thesis and so research surrounding it will be reviewed in some depth. 
The revolutionary one-step self-assembly employs four oligonucleotides which are then 
annealed together in buffer. On cooling, diastereomeric tetrahedra are formed as the 
thermodynamic product in high yield.75 Figure 1.28 illustrates this step and shows the overall 
structure of the first tetrahedron structure synthesised by Turberfield et al. 
 
 
 
 
 
 
 
Figure 1.28 – Diagram illustrating the 1 step synthesis of the DNA tetrahedron. Taken 
from 75.  
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Following on from this discovery, a variety of tetrahedron structures were reported by 
Goodman et al.85 These involved varying the side lengths to demonstrate the versatility of the 
assembly step. Dimers were also reported, by leaving a complimentary sticky-ended overlap 
on one edge to allow 2 tetrahedra to hydrogen bond to one another. Figure 1.29 demonstrates 
some examples of this family of tetrahedra visually. 
 
 
 
 
 
 
 
 
Figure 1.29 - (A) Tetrahedra with five 20-bp edges and one edge of 10 bp (lane 1), 15 
bp (lane 2), 20 bp (lane 3), 25 bp (lane 4), or 30 bp (lane 5). Tetrahedra with four 20-
bp edges, one 10-bp edge, and an opposite edge of 10 bp (lane 6), 15 bp (lane 7), 20 
bp (lane 8), 25 bp (lane 9), or 30 bp (lane 10). For both series the tetrahedra in the first 
and last lanes are illustrated by 3D models; the edge that is varied is marked with an 
arrow. (B) Linking experiments demonstrating stereoselectivity. A linking strand may 
join two 5×20/1×30-bp tetrahedra by hybridizing in 10-bp single-stranded gaps in 
both long edges.83 Figure taken from 85  
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These tetrahedra have a wide scope for functionality and variety. The hollow cavity also 
represents a clear opportunity to encapsulate a cargo. Research initially focused on filling this 
internal cavity with a protein. The first attempt by Erben et al involved covalently binding a 
small recombinant protein inside the tetrahedron.86 The central cavity was estimated to be 
able to encapsulate a sphere of a radius of 2.6 nm, equivalent to a folded protein of around 60 
kDa. Cytochrome C protein (12.4 kDa) was selected and conjugated to one of the four 
construction strands of the tetrahedron through a surface amine at the 5’ end of the 
oligonucleotide. The tetrahedron could then be constructed by combining the other three 
strands. By controlling the design of the tetrahedron, the position of the protein attachment 
can be adjusted as the turn of the duplex rotates about 13o per nucleotide down the turn.86 
Figure 1.30 illustrates the structure of the formed tetrahedron and outlines the control over the 
pitch and positioning of the attached protein, with each possible base position tested by gel 
electrophoresis. 
 
 
 
Figure 1.30 – A) structure of formed tetrahedron with nicks located on the vertices. 
B) Model of final product.  C) Diagram demonstrating effect of the rotation of the 
duplex on protein attachment point and gel electrophoresis experiment. Taken from 86 
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This publication only covered the encapsulation of the cargo and didn’t highlight any methods 
for subsequently releasing the cargo. As the surface amine attachment is a covalent bond, the 
bond would be very difficult to break without denaturing the protein. Various other covalent 
strategies for combining DNA with proteins have been reported including bifunctional 
crosslinkers87, click chemistry88 and disulphide bonds89. A reversible, non-covalent 
attachment between cargo and DNA structure became the challenge and this challenge began 
to be addressed when Goodman et al reported a reversible non-covalent coupling between 
proteins and oligonucleotides via a nickel mediated co-ordination bond involving Histidine 
tags on the protein and NTA (nitrilotriacetic acid) groups on the oligonucleotide.90 Once the 
coupling was initiated, the central Ni cation could be sequestered via use of a chelating agent, 
breaking the coupling.  
This coupling was then used by Bermudez et al. in 2012 in a tetrahedron-like structure and 
enhanced green fluorescent protein (EGFP) was internalised inside a DNA tetrahedron with i-
motif functionalities on the edges.91 The reversibility and subsequent release of the 
internalised EGFP was achieved through lowering the pH of the buffer to hydrolyse the Ni 
co-ordination bonds and form i-motifs in the vertexes which causes the tetrahedron to collapse 
in shape, subsequently releasing the protein from the structure. Unfortunately the low pH 
required for this denatured much of the protein activity. 
Another cargo encapsulation example involving the tetrahedron was reported by Crawford et 
al. in 2013.92 In this publication, catabolite activator protein (CAP), a transcription factor, was 
encapsulated inside a DNA tetrahedron. CAP intracellularly regulates up to 100 genes in the 
body and so was an interesting target as transcription factors activity can be blocked whilst 
inside a DNA cage as it cannot bind cellular DNA.92 If an external trigger was found that 
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Figure 1.31 – Model diagram of the DNA tetrahedron possessing the binding site for 
CAP and the subsequent encapsulation of CAP inside the central cavity. Taken from 
92. 
could release the protein whilst inside a cell, this would be a way to elegantly regulate gene 
expression.  
Encapsulation was achieved by incorporating a 22 bp sequence that matches the 22 bp 
recognition site on CAP into a DNA tetrahedron. This would then allow the CAP to recognise 
the site on the tetrahedron and bind inside (figure 1.31). 
 
 
 
The subsequent release of the CAP was demonstrated by addition of a nuclease to remove the 
DNA (effectively, if unselectively). However, it is reasonable to theorise any deformation of 
the binding site by an external factor would result in protein release such as DNA binding of a 
small molecule. 
The potential of the DNA tetrahedron as a strong candidate for cellular delivery of cargo has 
been discussed in depth and further literature reports of biological compatibility will be 
discussed further later in this introduction.  
1.2.3 DNA Origami 
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Figure 1.32 – Wide variety of shapes of folded DNA to form a) a square, b) a 
rectangle, c) a star, d) a smiley face, e) a pyramid of rectangles, f) a hollow triangle. 
All imaged by AFM. Taken from 93.  
A large branch of DNA nanotechnology that must be mentioned has become known as DNA 
origami.  DNA origami was first reported in 2006 by Paul Rothemund at the California 
Institute of Technology.93 It involves using a ‘construction strand’ which is an oligonucleotide 
of around 7kb. This construction strand is then manipulated with designed smaller ‘staple’ 
strands. These smaller oligonucleotides bind to the construction strand in a single step process 
to form the most energetically favourable formation. By carefully designing the staple strands, 
one is able to form controllable shapes of up to 100 nm in diameter.93 This technique allowed 
for a wide variety of recognisable shapes and structures to be synthesised and observed by 
AFM (figure 1.32). 
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This revolutionary work opened up many research opportunities to expand, not only on these 
2D arrays, but to form 3D structures out of folded DNA origami.94 The first and one of the 
most notable examples was by Gothelf et al. in 2009, synthesising a 3D box which possessed 
an openable lid which could be opened selectively on addition of an oligonucleotide or 
‘key’(figure 1.33).95  
 
 
 
Rigid enough to be characterised by AFM, cryo-EM and confirming the control of the lid 
through FRET experiments, this box certainly had an impact on the research area. The box 
has a few advantages over previously reported 3D DNA proposed cargo carriers as it can be 
opened by a specific trigger of any ssDNA or ssRNA, which could be tuned to specific 
Figure 1.33 – Model illustration of a) the origami construction square sections of 
folded DNA, functionalised with FRET pair (yellow star and red circle), b) fully 
constructed box with lid closed, allowing FRET to occur between the FRET pair. On 
addition of competing oligonucleotides (keys), the box is opened and halts FRET. 
Taken from 95.   
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cellular sequences. It also occurs under native conditions95 and unlike low pH conditions seen 
earlier91, biological cargo is unlikely to be damaged by the triggered release. 
Many groups reported similar boxes of differing size and shape to this original box, including 
a very similar box synthesised through closing a single open origami motif.96 Sugiyama et al. 
reported triangular, square and octahedral hollow prisms of DNA origami in simple 1 pot 
folding of a motif.97 A hollow DNA origami tetrahedron (figure 1.34) was also reported by 
Yan et al. in 2009 which attempted to address potential problems with the hollow sides to 
Turberfield’s tetrahedron.98  
 
 
 
Yet another approach to using DNA origami to construct 3D structures was reported by Shih 
et al.99 Here, the hollow cavity of the structures were replaced by honeycomb rods of DNA 
Figure 1.34 – A) Model drawing of completed origami tetrahedron. B) 2D drawing of 
the unfolded motif constructed. C) 2D drawing illustrating the folding of the 
construction strand. D) Model illustrating construction features of the tetrahedron. 
Taken from 98. 
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Figure 1.35 – TEM images of a variety of synthesised honeycomb DNA origami 
structures. Taken from 99. 
nanotubes. This pleated helical construction approach was aimed more at nanoscale device 
bearing applications rather than a cargo carrier. This was made possible by the much more 
rigid and solid structure of the design (figure 1.35).  
 
 
 
Overall, DNA origami was shown to be a very versatile method within DNA nanotechnology 
to achieve a wide variety of structural targets. With this versatility, and DNA being a 
biocompatible substance, it is no surprise it has gained so much interest as a capable cargo 
delivery medium to cellular systems. Research resulting from combining DNA 
nanotechnology with biological systems will now be reviewed.  
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1.3 DNA nanotechnology in Biological Applications 
1.3.1 DNA tetrahedron in cellular systems 
The DNA tetrahedron was first reported to be able to enter cells by Walsh et al. in 2011 
following its discovery in 2004.100 This is particularly interesting as the polyanionic nature of 
DNA makes cell membranes impermeable for dsDNA and ssDNA.101 Here, Turberfield’s 
original tetrahedron was fluorescently labelled with a fluorescent tag and incubated with 
human embryonic kidney cells (HEK line). The uptake and localisation was observed and 
measured with and without transfection agents by confocal microscopy. It was found that 
even in the absence of transfection agents, the tetrahedron was readily taken up by the cells. It 
was also found through FRET experiments that the tetrahedron remains intact for over 48 
hours inside the cells.100 
However, the article does not detail the mechanism by which the structure enters the cells. 
Instead it speculates on theories consistent with other nanoparticle uptake studies,102 
suggesting macropinocytosis, clathrin-mediated endocytosis, and caveolae-mediated 
endocytosis as possible entry mechanisms.103 All these suggestions are reasonable; because of 
the anionic nature of DNA and cell membranes, an active uptake mechanism seems the most 
likely as opposed to passive diffusion (due to electrostatic repulsions.)   
It wasn’t until 2014 that studies were reported that could begin to shed light on the most likely 
mechanism. Liang et al. reported that the DNA tetrahedron was taken up via caveolae 
mediated endocytosis.104 By utilising total internal reflection fluorescence microscopy 
(TIRFM) (figure 1.36) and tracking single fluorescently labelled tetrahedra, they were able to 
accurately assess the uptake pathway and subsequent intracellular transportation pathways.  
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Figure 1.36 – A) confocal images of cy3 labelled tetrahedron uptake from 2-12 hours. 
C) TIRFM images a to f showing one tetrahedron (indicated by arrow in frame a) and 
its uptake movements over time, highlighted by the blue arrow. D + E) 3D graphical 
presentation illustrating tetrahedron movement over time. Taken from 104 
 
 
The article managed to exclude other uptake pathways by creating conditions that would 
make other options impossible and by a process of elimination left only the caveolae 
dependent pathway possible. The major step came between attempting to differentiate 
between clathrin and caveolae dependent pathways. By treating the HeLa cells with methyl-β-
cyclodextrin (MβCD), which depletes cholesterol and disrupts caveolae and subsequently 
caveolae dependent endocytosis, the group were able to observe a decrease of approximately 
54%.104, 105 Conversely, by treating with sucrose to inhibit the effectiveness of the clathrin 
mediated pathway106, no change in uptake was observed, allowing the group to conclude the 
uptake mechanism reported.  
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Also following on from the reported cellular compatibility of the tetrahedron, delivery of the 
known chemotherapy drug doxorubicin with and without the DNA tetrahedron was reported 
to the breast cancer lines MCF-7 and MCF-7/ADR (doxorubicin resistant) in 2013.107 This 
exploited the DNA intercalating abilities of doxorubicin discussed earlier to combine the drug 
and the tetrahedron prior to cellular treatment (Figure 1.37). 
 
 
 
Not only was cytotoxic activity reported when the doxorubicin was delivered via the 
tetrahedron, most interestingly, it was able to by-pass doxorubicin resistance.107 It is well 
known that after repeated exposure to certain drugs, cancer cells can develop resistance 
mechanisms, one of which involves altering membrane proteins which regulate drug uptake to 
increase the efflux of the drug.108 As the DNA tetrahedron has been shown to be taken up by 
caveolae dependant endocytosis104, it will bypass any membrane protein based resistance built 
up against certain drugs. It was observed that by delivering doxorubicin via DNA tetrahedron, 
Figure 1.37 – Model diagram illustrating the construction of the doxorubicin loaded 
tetrahedron via intercalation, followed by cellular treatment with the formed conjugate. 
Taken from 107.  
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not only was total cellular doxorubicin content increased in doxorubicin resistant cells, but 
cell viability was significantly decreased when compared to treating with free doxorubicin.107 
Whilst this wasn’t the first report of using nanoparticles to deliver therapeutics to overcome 
drug resistance via altered uptake pathway, for instance, liposomal doxorubicin (marketed as 
Doxil) has been used in the clinic for over 25 years109, 110, it was one of the first instances of 
using a DNA nanostructure to overcome this type of resistance against a common therapeutic 
agent.  
Aside from delivery of classic chemotherapy drugs, the delivery of more novel therapies such 
as siRNAs (small interfering RNA) via DNA tetrahedron have been reported.111,112 The vast 
amount of options of functionality was neatly demonstrated in this report as a variety of gene 
silencing ligands were attached to the tetrahedron to produce promising results in the resulting 
cell testing. The conjugate was formed by synthesising a DNA tetrahedron from 6 
oligonucleotides to furnish a single stranded overhang to which a siRNA with the 
corresponding overhang could be attached (figure 1.38).111 This method of delivery not only 
demonstrated great versatility in gene selection, but also exhibited enhanced lifetimes of the 
siRNA in blood flow in mouse models from 6 mins with free siRNA to 24 mins when 
delivered by the tetrahedron. This gives a good indication that the DNA tetrahedron can help 
protect vulnerable or unstable cargo in cellular environments.  
Overall, the DNA tetrahedron has shown great promise as a drug delivery medium, with 
successful reports demonstrating great advantages.113 However, there has not been a reported 
example of a triggered cargo release following an external trigger inside cells.  
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1.3.2 Biological Applications of Other Types of DNA Nanostructures 
The DNA tetrahedron is not the only DNA structure reported to have applications in cellular 
delivery. DNA origami in the form of triangular origami nanotubes has shown to be 
compatible with cell systems and was reported to successfully deliver doxorubicin and bypass 
drug resistance mechanisms much in the same way as previously discussed.114 It is not clear 
whether the much larger DNA structures reported here are internalised via the same 
mechanism as the smaller tetrahedron, but high levels of drug loading due to sheer amount of 
DNA bases carrying the drugs such as doxorubicin. It will be interesting to see in years to 
Figure 1.38 – A) model illustrating construction of the tetrahedron from 6 
oligonucleotides and the subsequent self-assembly of the siRNA functionality. B) gel 
electrophoresis experiment confirming construction of tetrahedron. C) AFM images of 
tetrahedron on a surface. Taken from 111. 
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come, with the ever decreasing cost of synthetic DNA, which method will be more cost 
effective when treating in vivo. It is also worth noting that these publications do not discuss 
whether some of the cytotoxicity of the doxorubicin is diminished when delivered by DNA. 
DNA nanotubes are also capable of entering cells and were reported to be able to deliver 
integrated CpG-oligonucleotides.115 CpG-oligonucleotides are short ssDNA containing 
sequences of the nucleotide cysteine followed by guanine, separated by a phosphodiester 
group. They are active when unmethylated as they are recognised in cellular environments by 
receptors which initiate an immune response from the cell.116 They have been shown to 
stimulate immune responses against tumour antigens.116 However, they are vulnerable to 
nucleases and as ssDNA alone, cannot enter cells alone as their polyanionic nature leads to 
repulsion from cell membranes. By conjugating them inside DNA nanotube structures (figure 
1.39), the CpG oligonucleotides are protected and reported to enter cells in vivo within 
minutes. In mouse models, treatment with the conjugate resulted in increased levels of 
leukocytes; implicit of an immune response. Nanotubes alone did not result in immune 
response and as with other DNA structures, did not show cytotoxicity due to its high 
biocompatibility.115 
 
 
Figure 1.39 – Model illustrating the design and structure of the CpG-oligonucleotide 
integrated DNA nanotubes. Taken from 115. 
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Finally, it is worth noting the most widely studied nanocarrier for targeted drug delivery as a 
means of comparison to DNA nanostructures: Liposomes.117 Liposomes are phospholipid 
vesicles, made up of one or more lipid bilayers surrounding an aqueous central space. Their 
success can be attributed to a number of key attributes, the first being that they are capable of 
encapsulating both hydrophobic and hydrophilic molecules.118 The large aqueous center also 
allows encapsulation of large macromolecules such as DNA and proteins.119 This allows easy 
compatibility with a wide range of drugs. As phospholipids, they are biocompatible and have 
a wide range of physicochemical and biophysical properties that can be manipulated to 
control their characteristics in biomedical applications and targeting.120 Unlike DNA 
nanocarriers, some liposomal pharmaceuticals have become clinically approved. The most 
successful example of this is PEG conjugated liposomal doxorubicin.121 Encapsulating in this 
way has a number of advantages, the most notable being that it increases the half-life of 
doxorubicin in the blood while decreasing the peak levels of free drug in the blood. This 
increases accumulation in tumour tissue while decreasing cardiac muscle cell toxicity by 
reducing exposure here.122  
Despite the plethora of research, liposomal delivery modes have had a multitude of issues 
surrounding them, leading to dampened success in the clinic. Some of the main reasons for 
this are scaling up the manufacture of them is often problematic leading to unreliable product. 
Changes in manufacturing processes can also lead to broken down or denatured encapsulated 
compound.123 This highlights the importance of pursuing other nanocarriers such as DNA 
nanostructures.   
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1.4 Overview of Thesis  
This thesis aims to explore the effects of metallosupramolecular cylinders binding to different 
nucleic acid structures, with a particular focus on the DNA tetrahedron. The interaction 
between the cylinder and tetrahedron will be fully explored, examining any interactions for 
potential applications, along with possible biological compatibility. This research aims to set 
up findings that will plug the gap of externally triggered cargo release using DNA 
nanotechnology inside cellular systems.  
Chapter 2 will begin to investigate the iron-supramolecular cylinder’s affinity to a variety of 
DNA structures. It will then discuss the affinity to the DNA tetrahedron and explore any 
effects binding has to this structure. The enantiomers of the iron cylinder will also be explored 
and any differing binding behaviours to the tetrahedron investigated.  
Chapter 3 will investigate the biological activity of the cylinder-tetrahedron conjugate in 
cellular systems through established biological assays and microscopy. The potential effects 
of free tetrahedron and free cylinder when compared to conjugate will be investigated and 
following from this, the future applications of the complexes will be discussed.  
Chapter 4 explores a ruthenium cylinders ability to absorb light and induce DNA cleavage 
when bound to DNA. Activity at different wavelengths will be experimented and reported. 
Ruthenium cylinder photocleavage will be applied to the DNA tetrahedron with a view to 
trigger breaking open the tetrahedron with an external trigger. Finally, initial experiments on 
the potential application of the ruthenium cylinder as a photodynamic therapeutic agent in 
cells and the possible use of the tetrahedron in this setting are described. 
48 
 
Chapter 5 investigates the binding of iron, nickel and ruthenium cylinders to a looped region 
of HIV RNA, significant to the virus’ growth cycle. The effectiveness of inhibition and the 
anti-retro viral activity will also be discussed. 
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Chapter 2 
 
Interaction of an Iron supramolecular Cylinder with a DNA 
Tetrahedron and a Three Way Junction  
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2.1 Introduction  
Metallosupramolecular cylinders have shown unprecedented DNA binding to a wide variety 
of DNA structures including the major groove1 and most notably binding to and stabilising  
DNA Y-shaped replication forks or 3-way-junctions (3WJ).2 The binding is such that it causes 
bending and supercoiling of DNA (Figure 2.1).3, 4 
 
 
 
 
 
 
A wide variety of cylinders have exhibited similar behaviour, although none have shown the 
binding strength of the “parent” iron cylinder which has been previously synthesised within 
the group.3, 5-8  
 
 
 
 
 
Figure 2.1 - AFM images illustrating the effect of cylinder induced 
supercoiling of DNA. Taken from reference 4 
Figure 2.2 – Crystal structures of both the M (left) enantiomer and P (right) 
enantiomer. Taken from reference 10 
   M                    P 
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Being a di-nuclear triple helicate, it is inherently chiral and has two enantiomers (M and P) 
which can be separated using cellulose as a chiral stationary phase (Figure 2.2).9, 10  
As the DNA interactions of the cylinders are influenced by π-stacking interactions, shape and 
orientation are key to the cylinders’ behaviour. As such, the two enantiomers exhibit slightly 
different characteristics in their binding.11 Most interestingly, in crystallographic experiments 
involving a racemic mixture of the cylinder and a synthetic DNA 3WJ, only the M enantiomer 
was found to bind inside the 3WJ.12 In the field of DNA nanotechnology, this recognition and 
strength of binding would be of great interest as the characteristics can be used to develop 
triggered changes in conformational structure, release of cargo or quite simply delivery of the 
cylinder itself.  
The DNA tetrahedron synthesised by Turberfield is the first rigid 3D DNA nanostructure that 
has been synthesised in one, high yield simple step synthesis.13 The structure of this 
tetrahedron contains 3WJs at each apex and 17 bp of duplex DNA at the sides (Figure 2.3).  
 
 
 
 
 
Therefore, the parent cylinder should not only be able to bind to the structures involved here, 
but its binding strength could distort or trigger conformation changes. The tetrahedron is very 
rigid with a hollow cavity which could contain a cargo of a radius of up to 2.6 nm.14 Binding 
1. 95
o
C – 5 
mins 
2. 4
o
C – 10 
mins 
Figure 2.3 - Schematic diagram illustrating the formation of the 
tetrahedron. Taken from reference 13 
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events of the cylinder to the tetrahedron in the major groove and at the apex 3WJ could cause 
structure changes in the tetrahedron itself. Also the conjugate formed would itself be of 
biological interest due to the cytotoxicity of the cylinder and the inherent bio-compatibility of 
the tetrahedron due to its DNA building blocks and proven cellular uptake.15 
This chapter initially investigates the cylinders’ binding affinity to the DNA 3WJ when in 
competition with other DNA structures.  Investigation then moves on to assess the cylinder –
tetrahedron interaction, building on initial work completed by Siriporn Phongtongpasuk 
previously in the Hannon group. This is studied mainly by gel electrophoresis experiments to 
observe any possible band shifts which would confirm the presence of a conjugate. Further 
characterisation of the nature of this interaction is then attempted by different methods. Part 
two of the chapter aims to explore the possible differences between the cylinders two M and P 
enantiomers with regard to tetrahedron interaction. Any possible differences could shed more 
light on the nature of the overall interaction and whether site specific binding is possible to 
ascertain.  
2.2 Results and Discussion 
2.2.1 Part 1 – Cylinder 3WJ Binding 
Competition Gel Electrophoresis Assays 
The ability of the iron cylinder to bind inside a DNA 3WJ has been firmly established and 
discussed earlier.16 With so many other DNA structures involved inside cells, it is important 
to establish the binding preferences and to what extent the iron cylinder will preferentially 
bind to a 3WJ over another structure. To study this, a series of polyacrylamide gel 
electrophoresis (PAGE) experiments were undertaken.   
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PAGE is a widely used and very useful method in biochemistry for tracking and 
characterising protein or DNA samples as a function of their electrophoretic mobility.17 
Electrophoretic mobility depends on the bio-molecule’s size, shape and overall negative 
charge and refers to the speed of the migration through the gel.18 The experiment is performed 
by applying a potential difference across the gel (negative to positive) – effectively pulling the 
negatively charged sample through the gel. PAGE can be a native or denaturing experiment, 
depending on the conditions. Native refers to examining the samples in their stable (folded) 
biological state, for example, duplex DNA as it would be in solution. Denaturing refers to 
unfolding and breaking the biomolecule down to constituent parts, for example, down to 
single stranded DNA. In these experiments, a synthetic 3WJ was employed under native 
conditions. It consists of three 14-mer oligonucleotides containing unpaired bases in the 
centre to form the 3WJ (Figure 2.4).16 The small amount of bases in the duplex arms means 
that this 3WJ will be stable as a 3WJ below 4oC, but will dissociate into single strands at 
higher temperatures.19 This provides a perfect model as at room temperature, no 3WJ is 
formed unless it is stabilised by, in this case, the cylinder binding inside.  
 
 
 
 
 
By radiolabelling the oligonucleotide S3, the structure can be tracked easily in the gel with 
high sensitivity (~500 pM) which won’t be affected by cylinder binding which could prevent 
Figure 2.4 – 3 oligonucleotides that assemble to form a synthetic 3WJ. Taken from reference 16. 
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other visualising stains from binding to the DNA such as ethidium bromide. Figure 2.5 shows 
a native PAGE experiment where the 3 oligos are run with and without the iron cylinder at 
room temperature, clearly illustrating the band migration shift when the 3WJ is formed and 
when it is not.  
 
 
 
 
 
 
With this positive control in place, a range of DNA structures were mixed with the iron 
cylinder and the 3WJ DNA to establish whether cylinder would preferentially bind to the 3WJ 
or to the competitor, evidenced by a drop in intensity of the 3WJ band in a gel. The 
experimental design was to first mix and incubate 3WJ DNA and cylinder at a ratio of 1 
cylinder per 3WJ (1 hour incubation time). Competing DNA structures were then added at a 
1:1 ratio (30 min incubation time) and the samples run on a 15% native PAGE to quantify the 
proportion of intact 3WJ. The second experimental design was to add 3WJ DNA and 
competition DNA together prior to cylinder addition. Thus the cylinder has a choice of which 
structure to bind to and is not pre-bound in the 3WJ. Finally, in the third experimental design, 
cylinder was incubated with the competitor DNA before 3WJ DNA was added. Here the 
experiment probes the ability of 3WJ to pull cylinder away from another DNA structure to 
which it is bound. This range of experiments should give a clear view of cylinder-DNA 
Figure 2.5 – Autoradiogram of a 15% non-denaturing PAGE. Lane 1 containing the 3 oligos 
required for the 3WJ, unbound as ssDNA. One of which has been radiolabelled for 
visualisation. Lane 2 contains the oligos with the iron cylinder at 1:1 ratio, forming the 3WJ, 
causing the band shift. 
1      2 
3WJ 
ssDNA 
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structural binding preferences. Figure 2.6 shows the gel electrophoresis results obtained from 
these experiments (A, B and C). 
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Figure 2.7 – Graphical quantification of gels, showing the % of the 3WJ formed in 
each of the experimental conditions. Bottom showing all three graphs compared. 
Error bars show standard error of n=2 experiments.  
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It is clear that regardless of which DNA structure the cylinder is allowed to bind to initially, 
the cylinder overwhelmingly prefers to bind and thus stabilise the 3WJ. This was anticipated 
in gel A where the cylinder had already assembled and bound to the 3WJ and does not shift 
binding once competitor DNA was added. It was surprising however, that when the cylinder 
was bound to competitor DNA initially, in gel C; the cylinder still preferentially brought the 3 
oligos together to form the 3WJ. This shows that the binding constant is higher for the 3WJ 
than any of the other structures. The bottom graph of Figure 2.7 shows that the earlier the 
competitor DNA is added (from gel A-C), allows it to compete more, but only slightly in most 
cases. The ssDNA was the strongest competitor - in gel C only 53% of 3WJ was present. 
Whilst it is known that the cylinder can bind ssDNA, the reason for this competition is more 
likely from the ssDNA pairing with the unpaired oligos so that the DNA for the 3WJ is no 
longer available for the cylinder; rather than the cylinder binding directly to that 55-mer oligo. 
Further testing would be required to confirm this as a second band attributed to the 
radiolabelled strand binding to the ssDNA was not observed. This would be consistent with 
one (or both) of the other 2 strands binding to the ssDNA, but not the radiolabelled strand.  
Also, surprisingly, it was expected that the DNA tetrahedron would be able to compete well 
with the 3WJ for cylinder, considering that the structure itself contains four 3WJ-like 
structures. The angled nature of the junctions involved in the tetrahedron seems to be able to 
cause enough distortion to affect cylinder binding adversely. This in turn meant that little or 
no competition with the 3WJ was observed and it could be suggested that tetrahedron binding 
is at least 10 times weaker than 3WJ binding. The interaction with this interesting structure 
will still be studied in depth later in the chapter.  
From these experiments, it can be seen that the cylinder has considerable binding preference 
for the 3WJ over a variety of other structures at a 1:1 ratio. Physiologically however, 3WJs 
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are heavily outnumbered by duplex DNA base pairs. To begin to test this, an initial 
experiment was carried out to test the competition between the 3WJ and large excesses of 
plasmid DNA for the cylinder. The experiment was very similar to the previous competition 
gels, but the competition would be against the plasmid PuC19, up to a ratio of 5000 base pairs 
per 3WJ. Figure 2.8 shows the results of this experiment.  
 
 
-ve 
+ve 
PuC19 - + 
      1              2       3     4       5       6           
0
10
20
30
40
50
60
70
80
90
0 10 100 1000 5000
%
 3
W
J
Number of plasmid BP's per 3WJ
Figure 2.8 – Top: 15% PAGE showing the effect of increasing concentration of PuC19 plasmid on 
cylinder-3WJ binding. Lane 1 containing all 3 strands for the 3WJ. Lane 2 containing iron cylinder 
3WJ at 1:1 ratio (0.4µM), lanes 3-6 containing lane 2 components with plasmid concentrations of 
0.0015µM, 0.015µM, 0.15µM and 0.75µM respectively. Bottom: Bar Chart showing the 
percentage of 3WJ intact when compared to the single stranded band from the gel, each bar 
corresponding to lanes 2-6. Error bars show the standard error of the mean where n=2 (n = number 
of repeats).  
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This initial experiment was designed in the same way as experiment A, where the cylinder 
and 3WJ DNA were incubated together for 1 hour at RT, followed by addition of the plasmid 
DNA and an incubation of 30 minutes at RT. The experiment shows that by 5000 bp to 1 
3WJ, the proportion of 3WJ present is decreased by approximately 18% compared to the 
control. This result again confirms that the cylinder has a higher affinity to the 3WJ than 
duplex DNA. However, it must be noted that the plasmid was in a supercoiled state. With 
further experimentation, it would be interesting to use linear plasmid DNA that would provide 
large excesses of duplex DNA in a relaxed state as supercoiled DNA may be less accessible 
for cylinder binding.  
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2.2.2 Part 2a – Cylinder – DNA tetrahedron interaction     
2.2.2.1 Tetrahedron Synthesis and Characterisation 
The method used for the synthesis of the tetrahedron was replicated from a previous 
publication from Turberfield.13 Briefly, 4 synthetic strands of the correct sequences (see 
experimental) of DNA were purchased (Eurofins Operon) which had been HPLC purified. 
These strands were then annealed in TM buffer (10 mM Tris, 5 mM MgCl2 pH 8.0) by 
heating to 95oC for 5 minutes and cooling on ice for 10 minutes. The tetrahedron was then 
purified by passing through a 30K MWCO filter (Pierce) which retained the fully formed 
tetrahedron, whilst any unincorporated single strands which are smaller than 30k MW in size, 
were collected in the filtrate and disposed of. The purified tetrahedron could then be diluted to 
the desired concentration. No further purification was performed and the tetrahedron was 
stored in TM buffer unless otherwise stated.  
2.2.2.2 Polyacrylamide Gel Electrophoresis (PAGE)  
The tetrahedron was characterised by a number of methods. The first was gel electrophoresis, 
using native PAGE to examine and confirm the construction of the DNA tetrahedron.   
Figure 2.9 shows a native PAGE experiment illustrating the construction of the DNA 
tetrahedron. Lane 1 contains just 1 strand alone, lane 2 contains 2 of the strands, lane 3 with 3 
strands and lane 4, the fully annealed tetrahedron. Each of the migrations were in agreement 
with previously reported strand migrations.13 The absence of any secondary bands 
demonstrates the effectiveness of the synthesis; other bands in each lane would suggest 
secondary structures being formed. The approximate yield of the completed tetrahedron is 
estimated to be >95% by gel electrophoresis studies.13 
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2.2.2.3 Dynamic Light Scattering (DLS) 
Another method of characterisation used was dynamic light scattering (DLS also known as 
Photon Correlation Spectroscopy or Quasi-Elastic Light Scattering). This is a useful technique 
that can determine the size of particles in a solution down to around 1 nm. Most commonly, it 
is used to size materials such as nanoparticles, polymers, colliods or proteins.  Briefly, a laser 
is shone through a sample-containing solution at a known angle. The subsequently scattered 
light as it passes through the sample is then collected by a photon detector. The degree of 
scattering leads to a final calculation of the size of the particle in solution.  
DLS is not as commonly used in the field of DNA nanotechnology as most structures in the 
field do not have a uniform radius and are often not solid throughout, leading to complications 
in collecting a uniform scattering index. However, it was found that structures like the 
tetrahedron could provide sizing data which has allowed some experiments to be performed 
and some published data produced.20 The tetrahedron was diluted to 100 nM and scanned on 
the DLS, giving a hydrodynamic diameter of 13 nm (Figure 2.10). This is larger than previous 
1        2       3       4 
PD 
+Ve 
-Ve 
Figure 2.9 – Autoradiogram showing the construction of the DNA tetrahedron on 10% native 
PAGE. Lane 4: strand 1 only. Lane 3: strands 1 and 2. Lane 2: strands 1, 2 and 3 and finally lane 
1 containing all 4 construction strands to form the full tetrahedron. (Appendix fig.1) 
1      2      3     4 
WELLS 
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DLS experiments on the tetrahedron (9.08 nm).21  It is also slightly larger than the expected 
diameter of the tetrahedron, just over 6 nm. The DLS calculations assume that the sample is 
spherical, which exaggerates the size slightly due to the tetrahedral shape, along with some 
small instrumental margins of error lead to a figure slightly larger than expected. A hydration 
layer is also present which contributes to the extra size calculated. Despite these slight 
inaccuracies, DLS provides useful information as not only does it show particles of the correct 
region of size, it also shows that only one product is present in solution and no large aggregate 
or secondary structures are left after synthesis and purification.     
 
 
 
 
2.2.2.4 Atomic Force Microscopy (AFM) 
All AFM experiments were completed in the labs of Prof. Shao Fengwei by Dr Wang Liying 
from the institute of chemical biology, Nanyang Technological University. 
Figure 2.10 - DLS data of the DNA tetrahedron – showing one species in solution 
illustrated by the single peak. 
Peak 1:  12.68 d nm / 100%   St.dev : 3.986 nm  
Z average (d.nm) : 26.90            PDI   : 0.138            PDI Width :  6.403 
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Whilst the gel electrophoresis and DLS results give a good idea of the size and amount of 
base pairs involved, they don’t give a full characterisation that the tetrahedron has been 
formed and it cannot be said with certainty that a tetrahedron is the shape of the structure 
formed here. Atomic force microscopy (AFM) is the only current method that provides both 
full structural and mechanical information at high resolution of nanoscale materials.22 Briefly, 
AFM works by moving a very fine tip (approximately 2 nm) over a surface. The tip is 
attached to a sensitive cantilever to which a laser can record any deflections corresponding to 
any analyte the tip has been dragged over. This builds up a surface topography that can be 
plotted and imaged computationally.23 AFM is a powerful tool in analysing biological 
samples, such as DNA, as it can be performed in an aqueous environment as opposed to 
drying the sample. Drying a DNA sample can lead to deformations in DNA structure, leading 
to inaccuracies when establishing structure. 
The tetrahedron synthesised here was analysed in collaboration with Dr Wang Liying and 
Prof. Shao Fengwei at the Nanyang Technological University in Singapore by AFM. Figure 
2.11 shows the 3D image created of the sample. The figure shows remarkably clear 3D 
tetrahedra, all in the size range that was expected. This very positive result fully confirms and 
characterises the synthesised tetrahedron here. The size calculation, show also in Figure 2.11, 
of 19.2 ± 1.5 nm is larger than modelling suggests and the DLS result. However, this was not 
unexpected as AFM measurements also detect the hydration layer surrounding the DNA, 
along with the added width of the AFM tip of 2 nm leading to a slightly larger value than 
other methods of measurement. This size figure is included for means of comparison for later 
on in the chapter.  
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Figure 2.11 – AFM image of the DNA tetrahedron (top), size distribution of tetrahedra (middle). 
Height profiles of four separate tetrahedra (bottom) Figures produced by Dr Wang Liyang, 
Nanyang Technological University, Singapore. 
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2.2.3 Interaction between the cylinder and the Tetrahedron 
2.2.3.1 Polyacrylamide Gel electrophoresis 
Now the structure of the tetrahedron has been characterised, the interaction between the iron 
cylinder and the tetrahedron can be studied. The first experiment used was again gel 
electrophoresis, employed in a similar way to that used to characterise the tetrahedron. 
Different samples of DNA tetrahedron were incubated with increasing concentrations of iron 
cylinder at ratios of 0:1, 2:1, 4:1, 6:1, 8:1, 10:1, 0:1 (cylinder to tetrahedron). Figure 2.12 
shows the gel image produced. It is shown here that with increasing cylinder concentration, 
the migration of the DNA tetrahedron is increased, though the effect is small. This is 
interesting as one would expect the migration to be slowed down with the conjugate 
becoming bulkier and some of the negative charge of the DNA balanced by the positively 
charged cylinder. The opposite of the expected trend occurs and this suggests that the cylinder 
Figure 2.12 – Autoradiogram of a 10% non-denaturing PAGE experiment. Lanes 1 and 7 
containing DNA tetrahedron alone as reference (0.5 µM), Lanes 2-6 contain increasing amounts of 
iron cylinder with the DNA tetrahedron with ratios at 2:1, 4:1, 6:1, 8:1 and 10:1 relating to cylinder 
concentrations of 1, 2, 3, 4 and 5 µM respectively. Gel was run in 1 x TB buffer (89 mM Tris, 89 
mM Boric acid, pH 8.3) at room temperature for 3 hours at 10v/cm. 
1         2         3        4       5        6        7 
[Fe2L3]4+ 
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is binding to the DNA and causing it to compress, becoming a smaller sized structure, 
speeding the migration through the gel. It could be that the two mentioned effects compete 
with each other, but the size compression has the overriding effect on the electrophoretic 
mobility of the tetrahedron.  
It is important to prove the cylinder is still intact and bound to the DNA throughout the entire 
experiment. This was done by running a non-radiolabelled sample of DNA and the band 
containing the conjugate at a ratio of 5:1 (cylinder: tetrahedron) was excised from the main 
gel. The conjugate was then liberated from the band using the ‘crush and soak’ method (see 
experimental). The resulting solution was then observed using UV-Vis spectroscopy to find 
the characteristic absorbance at 573 nm attributed to the MLCT band of the iron cylinder 
(Figure 2.13). This information shows that at least some of the cylinder remains intact, does 
not break down and that the cylinder is bound to the tetrahedron and migrates with it through 
the gel 
 
 
 
 
 
 
 
Figure 2.13 – UV Vis spectrum of the excised band showing peak at 573 nm, 
confirming the presence of the iron cylinder in the band. 
82 
 
2.2.3.2 Dynamic Light Scattering (DLS) 
As the first experiment suggested the cylinder compressed the DNA tetrahedron, DLS was 
used to further explore this hypothesis. As previously discussed, DLS can provide valuable 
information about a particle in solution and therefore should be able to track any size changes.  
 Samples of DNA tetrahedron were prepared at 100 nM and iron cylinder solution titrated in 
to achieve the ratios of DNA tetrahedron to Cylinder of 1:0, 1:2, 1:4, 1:6 and 1:8. At each 
ratio the sample was scanned on the DLS to find an estimate of the diameter in solution. 
Figure 2.14 shows a line graph of the results obtained. It is shown that as increasing amounts 
of cylinder are added, the hydrodynamic diameter decreases (overlay of size distribution 
shown in Figure 2.23). This result backs up the previous theory that the cylinder’s binding 
forces compression of the DNA into a smaller size. The decrease is by approximately 30% by 
8 equivalents of tetrahedron and higher equivalents. DLS remains a useful tool here as it 
Figure 2.14 – DLS size by number data of the DNA tetrahedron (100nm) as increasing 
amounts of cylinder is added by ratios of 0, 2,4,6,8 to 1 tetrahedron, relating to 
concentrations of 0, 200, 400, 600 and 800 nM of cylinder respectively. Error bars show 
the standard error of the mean size (n=3). 
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shows the size decreasing comparatively to the tetrahedron alone. This shows that binding of 
the cylinder to the tetrahedron has a compressing effect on the structure. 
 
2.2.3.3 Atomic Force Microscopy  
All AFM experiments were completed in the labs of Prof. Shao Fengwei by Dr Wang Liying 
from the institute of chemical biology, Nanyang Technological University. 
By employing AFM again, it was hoped that the cylinder-tetrahedron size reduction effect 
would be able to be visualised. Cylinder and tetrahedron were incubated together at a ratio of 
4 to 1 before being imaged by AFM. Figure 2.15 shows the image produced by this 
experiment. The once sharp edges of the tetrahedron are now much less clear and more 
rounded, suggesting the DNA is been compressed here, possibly by the cylinder binding into 
the 3WJ and flattening the emerging edges, although AFM cannot reveal where exactly the 
cylinder is bound. The tetrahedra has also become less defined than before, suggesting the 
structure as a whole has lost some rigidity and is not fully resisting the AFM tip now, leading 
to a less sharp reading of the structure. Figure 2.15 shows also the diameter of the resulting 
conjugate from 19 nm to 12 nm – a decrease of 37% which is a dramatic decrease. When 
compared with the previous DLS measurement at 4:1, the decrease is just 18%. It is not clear 
what causes this disparity but the most likely source of difference is instrumental. Overall, it 
can be concluded that the iron cylinder binds to the DNA tetrahedron and on doing so, causes 
a deformation in the structure, dramatically reducing its rigidity, size and thus the volume of 
the central cavity.    
84 
 
 
7 8 9 10 11 12 13 14 15 16 17 18 19 20
0
10
20
30
40
N
u
m
b
e
r
Size / nm
12.8 ± 1.2 
nm 
Figure 2.15 – AFM image of the DNA tetrahedron with cylinder bound (1:4) (top), size 
distribution of tetrahedra-cylinder conjugate (middle). Side size profile of 4 separate tetrahedra 
(bottom). Figures produced by Dr Wang Liyang, Nanyang Technological University, Singapore. 
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2.2.3.4 Stabilisation Effect 
In solution alone, the cylinder breaks down over time by the ligands becoming liberated from 
the iron metal. As the cylinder has a unique MLCT absorption band at 573 nm (ϵ = 16900)11  
UV-Vis spectroscopy can be used to monitor the concentration of intact cylinder over time to 
ascertain the rate of degradation. It would be interesting to see whether, when bound to the 
tetrahedron, the cylinder would experience enhanced stability in solution. In this regard, two 
solutions in TM buffer containing identical concentrations of cylinder, one free in solution 
and the other bound to the DNA tetrahedron were prepared. These solutions were then 
monitored over time by UV spectroscopy, observing the absorbance at 573 nm. Figure 2.16 
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Figure 2.16 – UV-Vis data illustrating the breakdown of the iron cylinder at room 
temperature (top) and at 70oC (bottom). Green representing when the cylinder is bound to 
the tetrahedron and blue representing the free cylinder. 
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shows the concentration of the two solutions when kept at room temperature and another 
experiment at 70oC.  When bound to the tetrahedron, at room temperature, no degradation is 
observed at all over 12 days. In fact a very small increase in absorption (<1%) was observed 
which was attributed to small amounts of water evaporating even though the cuvette had a lid. 
Free cylinder, however, almost completely degrades in the same time period. At an elevated 
temperature of 70oC, the free cylinder is fully degraded within 40 minutes, whereas the 
conjugate has only slight degradation over the same period. The DNA binding helps protect 
the iron-nitrogen coordination from hydration when in solution. This is particularly useful in 
biological applications as the cytotoxic cylinder would remain intact for longer at 
temperatures of 37.5oC in vivo, increasing the half-life inside the body and thus increasing 
potential bio-availability, creating an overall more effective therapeutic.  
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Figure 2.17 – Cellulose column showing iron cylinder enantiomer separation. The M 
enantiomer is eluted first, followed by the P. Eluted with 0.2M NaCl solution. 
2.2.4 Part 2a – Assessing different characteristics of Cylinder Enantiomers 
2.2.4.1 Separating and characterising the Cylinder Enantiomers  
The cylinder is a triple helicate, and therefore is inherently chiral. As discussed earlier, it has 
two enantiomers in a racemic mixture. These enantiomers are known as M and P, to denote 
the right and the left handed chiral twists enantiomers. These enantiomers can be separated 
using column chromatography with cellulose as the stationary phase. Figure 2.17 shows the 
enantiomers visually separated as two fractions on the column, with the M enantiomer eluting 
before the P. 
 
 
 
 
 
 
 
  
It is interesting to separate the enantiomers and observe their behaviour as previous reports 
have suggested that each have differing DNA binding properties. The M enantiomer was 
reported to have a stronger binding constant with the major groove in DNA than the P and 
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only the M enantiomer was observed inside 3-way-junction DNA in crystallographic 
experiments.11 However, gel studies performed previously in the group show that both the M 
and P enantiomers can stabilise the DNA 3WJ. This suggests that M enantiomer potentially 
has a more favourable spatial fit inside 3WJ and major groove DNA than the P enantiomer 
and therefore could have differing binding strengths to the DNA tetrahedron.  
2.2.4.2 Circular Dichroism (CD) 
One of the experiments used to test the enantiomer separation and purity of the products was 
by circular dichroism (CD). Circular dichroism is exhibited as the effect of chiral molecules 
have on passing circularly polarised light, specifically the differential absorption of left and 
right handed polarised light.24 In a racemic mixture of the cylinder, the CD signals of each 
enantiomer cancel each other out as they are present in equal concentrations. Once separated 
the enantiomers CD signal can be observed. Pure enantiomers would give exactly the same 
intensity of CD signal mirrored to each other when overlaid, provided the concentrations of 
the enantiomers and path length are the same. By scanning exact concentrations of each 
enantiomer, the resulting absorption spectra should mirror one another in shape and intensity. 
Figure 2.18 shows close to enantiopure samples of each enantiomer were achieved with each 
enantiomer mirroring the CD peaks in each of the spectra. Here, the M enantiomer is seen to 
have a slightly more intense CD peaks than the P. This is explained simply by the eluting 
order of the enantiomers from the cellulose column. The M enantiomer is eluted first, but the 
slow moving smearing nature of the eluting band causes some enantiomer to drag behind into 
the P enantiomer band. Much effort was put into improving enantio-purity by increasing the 
amount of stationary phase and decreasing sample load to enhance band resolution. To obtain 
P enantiomer of purity comparable to M enantiomer, it was necessary to run the enantiomer 
through multiple cellulose columns to remove as much M enantiomer as possible.  
89 
 
During this process, it became apparent that in solution at room temperature, purified 
enantiomers could re-racemise to form its opposite enantiomer at a slow rate. This was 
minimised by freeze drying and de-salting the fractions quickly. Through this it was possible 
to obtain highly pure enantiomers. 
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Figure 2.18 – CD data of the M and P enantiomers, illustrating the mirrored nature 
of the CD signals. Samples were of 15 µM cylinder with a 1 cm path length. 
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2.2.4.3 Chiral Shift Reagent  - Λ-TrisPhat 
To fully ascertain whether pure enantiomers where obtained by this method, the chiral shift 
reagent Λ-TrisPhat tetrabutylammonium salt ([Tetrabutylammonium] [Δ-tris(tetrachloro-1,2-
benzenediolato)phosphate(V)]) was used (Figure 2.19). This chiral anion is configurationally 
stable in solution and can be isolated as either isomer. It has also been shown to be able to 
form diastereomeric ion pairs with chiral metal-ligand complexes which then exhibit different 
chemical shifts in 1H NMR spectroscopy.25  
By adding Λ-TrisPhat to samples of racemic cylinder and also to sample of the M and P 
enantiomers, it was found that the anionic counter ion interacts each of the enantiomers 
differently. Figure 2.20 shows the 1H NMR data of the racemic iron cylinder alone. On 
addition of the chiral anion, 1H environments CH2, Him and 5py split into two more sets of 
peaks.  
Figure 2.19 - Λ-TrisPhat tetrabutylammonium salt structure, taken from Sigma Aldrich 
product web page. 
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Figure 2.20 – H1 NMR data of racemic iron cylinder with assignments (top) and racemic 
cylinder with a 1:1 molar equivalent of Λ-TrisPhat (bottom) illustrating the peak splitting of 
Him, 5py and CH2 as the chiral anion interacts with each of the enantiomers differently.  
92 
 
This is due to the anion interacting and binding to each of the cylinder enantiomers 
differently. This causes the proton environments to change and shifts the signals. The cylinder 
environments the TrisPhat is interacting with is the central bridging section of the ligand 
(CH2) and the metal coordination site. Previous work in the group performed by Dr Lucia 
Cardo has concluded that the up field shift of the new peaks on CH2 is the anion binding to 
the M enantiomer and the down field shifts of the new peaks at Him and 5py is binding to the 
Figure 2.21 – H1 NMR data M enantiomer of the iron cylinder (top) and P enantiomer of the 
iron cylinder (bottom) both with a 1:1 molar equivalent of Λ-TrisPhat illustrating the leak of 
peak splitting. 
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P enantiomer. This was done by spiking an enantiomer sample with a known amount of the 
other enantiomer and quantifying the new environment to confirm which enantiomer was 
responsible for each of the new peaks.  
Using this model, Λ-TrisPhat was added to each of the separated enantiomers at a 1:1 molar 
ratio to look for the presence of any of the opposite enantiomer, which would be evidenced by 
new peak splitting in small amounts. Figure 2.21 shows the 1H NMR data of this experiment. 
From this, no peak splitting was observed in the areas of interest. With this information, the 
cylinder enantiomers could be considered to have an acceptable level of enantiomeric purity 
(<95%) which could be used for further experimentation. 
 
2.2.5 Part 2b - Differences in the enantiomer effects on the Tetrahedron. 
2.2.5.1 Polyacrylamide Gel electrophoresis 
As previously highlighted, the M enantiomer has been shown to have a higher binding affinity 
to the major groove in linear DNA and was the only enantiomer found to bind inside the 3-
way-junction in crystallographic experiments, even when racemic cylinder was used. To see 
the effect the different enantiomers might have on the DNA tetrahedron, a similar gel 
electrophoresis experiment was performed as before. This time the DNA was incubated with 
the same concentrations of each enantiomer and the effect of each compound analysed. This 
experiment backed up previous investigation that the M enantiomer binds more strongly. 
Figure 2.22 shows that the lanes containing the M enantiomer have a slightly greater effect of 
speeding migration through the gel than the P enantiomer. This suggests that the stronger the 
binding of the cylinder, the stronger the deformation of the rigid tetrahedron structure into a 
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smaller, faster migrating conjugate. Another explanation could be that both enantiomers bind 
equally well, but the binding of the M enantiomer has a bigger structural effect than the P 
enantiomer. 
 
 
 
 
 
 
 
 
 
 
2.2.5.2 DLS 
The earlier DLS experiment in which racemic cylinder was titrated into tetrahedron was now 
repeated with each of the enantiomers. This was done to attempt to quantify the earlier gel 
electrophoresis result in the expectation that the M enantiomer would decrease the overall size 
of the DNA tetrahedron more effectively than the P enantiomer. Figure 2.23 shows the DLS 
data obtained from this experiment, with the previous racemic experiment data overlaid for 
comparison. From the scatter graph, it can be seen that the expected trend is very neatly 
Figure 2.22 – Autoradiogram of a 10% non-denaturing PAGE experiment. Lane 1 and 6 
consisting of DNA tetrahedron only (1µM), lane 2 and 3 containing tetrahedron with P 
enantiomer and tetrahedron at ratios of 5:1 and 10:1 respectively, with cylinder 
corresponding cylinder concentration of 5µM and 10µM respectively. Lanes 4 and 5 
containing tetrahedron with P enantiomer and tetrahedron at ratios of 5:1 and 10:1 
respectively, with cylinder corresponding cylinder concentrations of 5µM and 10µM 
respectively.  
 1      2     3      4       5     6 
P     2P   2M   M 
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illustrated, with the M enantiomer having the most effect on the tetrahedron, with the P 
enantiomer having the least. In comparison, the racemic cylinder sits between two. The 
difference is very subtle as previously shown by the gel electrophoresis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.23 – Top) DLS size data of the DNA tetrahedron (100 nM) as increasing amounts of 
different enantiomers of iron cylinder are added to create ratios of 0,2,4,6,8 to 1 tetrahedron, 
relating to concentrations of 0, 200, 400, 600, 800 nM of cylinder respectively. R = racemic 
mixture of cylinder enantiomers. M = M enantiomer. P = P enantiomer. Error bars show the 
standard error were n=3. Bottom) Overlays of an experiment of separate titrations showing the 
decrease in size.
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It is worth noting the range in the distribution of the size is wide, and this is probably due to 
the none-spherical and none solid structure of the tetrahedron causing a range of scattering. 
From the overlays, however, it is clear the entire range can be seen to shift to the left on 
increasing cylinder, showing an overall decrease in size.  
2.3 Conclusions 
Overall, in the initial parts of this chapter, it was shown that the iron cylinder has very high 
affinity to a synthetic DNA 3WJ and prefers to stabilise this structure over a wide range of 
other common DNA structures. From this, in part 2a, the cylinder was shown to also bind to a 
DNA tetrahedron. Further investigation into this binding led to the discovery of a very 
interesting interaction between the two; that cylinder binding lead to deformation and 
structural compression of the tetrahedron. This interaction was characterised through various 
techniques and a similar result obtained through each technique. In part 2b the cylinder 
enantiomers were separated and characterised successfully, following on from previous group 
work showing that the M and P enantiomers may behave differently with regards to DNA 
binding. In this respect, both enantiomers were shown to cause compression on interaction 
with the tetrahedron, with the M enantiomer shown to be more slightly more effective that the 
P enantiomer.  
The interaction discovered here is a novel one between a small molecule and DNA 
nanostructure. As DNA nanostructures with hollow central cavities have been widely 
championed as cargo vessels for drugs, an interaction which would potentially see an 
internalised cargo pushed out on addition of cylinder is very exciting. The conjugate formed 
between the iron cylinder and the tetrahedron also has great biological potential which will be 
studied further in the following chapter.  
97 
 
2.4 Experimental 
Materials 
All Chemicals were purchased from Sigma Aldrich unless otherwise stated. Pre-mixed 
Acrylamide / Bisacrylamide Stabilized Solution for gel electrophoresis was purchased from 
National Diagnostics. ATP-32 was sourced from Perkin Elmer. All oligonucleotides were 
purchased reverse phase HPLC purified from Eurofins. T4 Polynucleotide kinase was 
purchased from New England Biolabs. 
 
Synthesis of Parent Ligand (L: C25H20N4) 
4,4’Methylenedianiline (1.99g, 0.01 mol) was dissolved in ethanol (10 ml). To this solution, 
pyridine-2-carboaldehyde (1.90 ml, 0.02 mol) was added. The solution was then left to stir 
overnight. The yellow precipitate formed was then collected by vacuum filtration. The crude 
product was then purified by re-crystallisation from ethanol (3.50 g, 93% yield). The product 
is a pale yellow solid.  
 
Mass Spectrum (ESI): m/z = 399 [M+Na] 
1H NMR (300 MHz), CDCl3, 298K): δ 8.71 (2H, d, J = 3.9 Hz, 6py), δ 8.63 (2H, s, J = Him), δ 
8.22 (2H, d, J = 7.0 Hz 3py), δ 7.82 (2H, td, J = 8.3, 1.9, 0.6 Hz, 4py), δ 7.40 (2H, ddd, J = 
7.6, 4.9, 1.2 Hz, 5py), δ 7.30 (8H, m, Pha and Phb), δ 4.08 (2H, s, CH2) 
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Synthesis of the triple stranded iron helicate [Fe2(L)3]Cl4 
Ligand (3.0g, 0.008 mol) was dissolved in methanol (400 ml). Iron (II) chloride tetrahydrate 
(1.06 g, 0.005 mol) was then added to the solution and the resulting solution was brought to 
reflux at 65oC for 3 hours. The solution was then taken to dryness in vacuo. The crude 
product was then dissolved in minimal amounts of methanol (10 ml) and excess methanolic 
ammonium hexafluorophosphate added. The resulting precipitate was collected by filtration 
and washed with water (2 x 10 ml) and then diethyl ether (5 x 25 ml). The filtrate was then 
suspended in methanol and stirred with Dowex until the product had dissolved. The Dowex 
was then filtered off. The filtrate was taken to dryness in vacuo, and then redissolved in a 
minimum amount of methanol. Excess diethyl ether was added until the product precipitates, 
the final product was filtered and washed with ether and dried (1.65g, 59.7%). The final 
product was a crystalline purple solid.   
 
Mass Spectrum (ESI): m/z = 425.5 [Fe2L3]Cl
3+ , 310 [Fe2L3]
4+ 
1H NMR (300 MHz), CD3OD, 298K): δ 9.13 (2H, s, Him), δ 8.71 (2H, d, J = 7.2 Hz, 6py), δ 
8.48 (2H, t, J = 7.8, 3py), δ 7.84 (2H, ddd, J = 5.6, 4py), δ 7.44 (2H, d, J = 5.2, 5py), δ 7.05 
(4H, broadened,  Pha/b), δ 5.62 (4H, broadened, Pha/b), δ 4.07 (2H, s, CH2) 
UV-Vis (H2O), λmax (ϵmax/dm3mol-1cm-1) 584 (16900) nm   
 
Radiolabelling of Oligonucleotides 
A mixture of 9.6 µl of MilliQ water, 2 µl of 10x T4 polynucleotide kinase buffer (New 
England Biolabs), 2 µl of bacteriophage T4 polynucleotide kinase (New England Biolabs) , 
2.4 µl of 100 µM of oligonucleotide and 4 µl of 32P ATP (6000 Ci/mmol – Perkin Elmer) was 
added to a 1.5 mL eppendorf. The mixture was vortexed gently (2secs), centrifuged (3000 
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rpm, 5 secs) and then incubated at 37 oC for 1 hour. The enzyme was then deactivated by 
heating to 80 oC for 3 minutes. The labelled oligonucleotide was then purified by adding 200 
µl of PNI Buffer (QIAquick nucleotide removal kit) and the total solution transferred to a 
QIAquick 2 ml spin column. It was then centrifuged at 6000 rpm for one minute. The spin 
column was transferred to a new collection tube and 500 µl of PE buffer was added. The tube 
was again spun at 6000 rpm for 1 minute. This wash was repeated followed by centrifugation 
at 13000 rpm for 1 minute to remove all buffer and pellet the DNA in the tube fully. 24 µl of 
ultrapure water was added to the tube and left for 5 minutes. The labelled DNA strand was 
then centrifuged from the tube into an eppendorf at 13000 rpm for 2 minutes to obtain a 10 
µM stock solution of radiolabelled oligonucleotide.    
 
 
Preperation of non-denaturing Polyacrylamide Gel for electrophoresis 
Two glass plates for vertical electrophoresis were placed on top of one another, the smaller on 
top of the larger. The plates were separated with plastic spacers each side. The plates were 
held together with 4 bulldog clips or set in a Bio Rad casting chamber depending on the size 
of the plates. The desired percentage of 30% 37.5:1 Acrylamide to Bisacrylamide (National 
Diagnostics) was created by diluting with TB buffer and deionised water up to 50 mL in a 
falcon tube (final buffer concentration of 89 mM Tris base, 89 mM Boric acid, pH 8.3). A 
freshly made 10% ammonium persulphate solution was then added (232 µl), followed by 25 
µl of TEMED. The falcon tube was mixed carefully by inversion to disperse any air bubbles. 
Using a 50 ml pipette and pipette gun, the gel solution was transferred into the glass plates. 
The gel was left to set fully (approximately 45 mins). The set gel was then wrapped in paper 
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towel soaked in deionised water and then cling film to prevent the edges of the gel drying out, 
before being refrigerated until needed.   
 
Competition PAGE Experiment 
Three 14-mer reverse phase HPLC purified DNA oligonucleotides (Eurofins) of sequence: 
S1: CGGAACGGCACTCG (radiolabelled) 
S2: CGAGTGCAGCGTGG 
S3: CCACGCTCGTTCCG 
were mixed in stoichiometric quantities in TBN buffer (9µl) (89 mM tris base, 89 mM boric 
acid, 100 mM NaCl, pH 8.0) to a final concentration of 0.4 µM per strand, competition DNA 
(sequences below) and iron cylinder (1µl) were mixed in also to a final concentration of 0.4 
µM (10µl final). The order these were mixed depended on the experiment (A = competition 
DNA last, B = Cylinder last, C = 3WJ DNA last). Before the final component was added, 
solutions were incubated for 1 hour and a further 30 mins on addition of final component, all 
at room temperature. 5 µl of 30% glycerol was then added to each sample to help the sample 
sink into the gel wells whilst in buffer. Samples were then loaded onto a 15% non-denaturing 
polyacrylamide gel and run at 11v/cm for 3 hours. The gel was then exposed to a phosphor 
plate and imaged on a molecular imager and the image quantified using Quantity One 
software (Bio-Rad). 
Competitor DNA sequences (5’-3’): 
ssDNA (single stranded DNA – 55 mer): 
ACATTCCTAAGTCTGAAACATTACAGCTTGCTACACGAGAAGAGCCGCCATAGTA 
DS26 (double stranded DNA – x2 = 26 bp): 
CCTTCACGCGAACGTAATCCTAGGATTACGTTCGCGTGAAGG 
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hTelo (Human telomeric guanine quadruplex – 22 mer): 
AGGGTTAGGGTTAGGGTTAGGG 
c-MYC (c-MYC promotor guanine quadruplex – 22 mer): 
TGAGGGTGGGTAGGGTGGGTAA 
TAR RNA (Trans-activation response element RNA in HIV virus – 31 mer): 
GGCCAGAUCUGAGCCUGGGAGCUCUCUGGCC 
PuC19 Plasmid 
Tet (DNA tetrahedron – 220 bp) 
Composition of preparation detailed below 
All competitor DNA (aside from Tet and Puc19 plasmid) was annealed by heating to 90oC for 
5 mins followed by cooling on ice to ensure correct structure. All sequences purchased from 
Eurofins. 
Structures of competitor DNA with secondary structure shown below. 
 
c-MYC26: 
 
 
 
hTelo27: 
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TAR RNA28: 
 
 
 
Construction of DNA Tetrahedron 
Stoichiometric amounts of each of 4 HPLC purified oligonucleotides (Eurofins) of sequences: 
17T1: 
ACATTCCTAAGTCTGAAACATTACAGCTTGCTACACGAGAAGAGCCGCCATAGTA 
17T2:  
TATCACCAGGCAGTTGACAGTGTAGCAAGCTGTAATAGATGCGAGGGTCCAATAC 
17T3: 
TCAACTGCCTGGTGATAAAACGACACTACGTGGGAATCTACTATGGCGGCTCTTC 
17T4: 
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TTCAGACTTAGGAATGTGCTTCCCACGTAGTGTCGTTTGTATTGGACCCTCGCAT   
were mixed in TM buffer (10mM Tris base, 5mM MgCl2, pH 8) (max concentration of 1 µM 
per strand)  in an Eppendorf. The mixture was then heated to 95 oC in a thermal block for 5 
minutes. On cooling at room temperature for 30 seconds, the Eppendorf was placed on ice for 
5 minutes and then centrifuged for 5 seconds. The product was then purified and concentrated 
to desired concentration in a 30K MWCO filter (Pierce).   
 
 Tetrahedron Gel Electrophoresis 
 Tetrahedron samples (17T1 radiolabelled) (1 µM) were prepared in 1.5 ml Eppendorfs in 1 x 
TM Buffer (10mM Tris base, 5mM MgCl2, pH 8) and cylinder added to achieve the desired 
ratios. The samples were incubated at room temperature for 60 minutes and then on ice for 10 
minutes. 5 µl of 30% glycerol was then added to each sample to help the sample sink into the 
gel wells whilst in buffer. The samples were then loaded into separate lanes on a 10% non-
denaturing polyacrylamide gel in the desired order. 10µl of gelpilot™ (Qiagen) was added to 
the adjacent wells to the samples to track the progress of the experiment. The gels were run at 
a constant 11V/cm of gel at room temperature for 5 hours. The gel was extracted from the 
glass plates using a sheet of Whatman paper and wrapped in clingflim. The gel was placed 
inside a developing cassette with a white phosphor film placed over for 1 hour. The phosphor 
film was imaged using a molecular imager to produce an autoradiogram.   
 
Dynamic Light Scattering – DLS 
DNA tetrahedron samples were prepared and diluted to 100 nm with iron cylinder to achieve 
ratios of 0:1, 2:1, 4:1, 6:1 and 8:1 relating to concentrations of 0, 200, 400, 600 and 800 nM 
respectively before being passed through a 1 µM syringe filter (Pall). Samples were incubated 
104 
 
at room temperature for 1 hour and then on ice for 1 mins. The samples (1 ml) were then 
transferred to separate disposable sizing cuvettes and then scanned on a Malvern Zetasizer 
nano for a total of 60 runs (3 x 20) to provide a size by number distribution. 
 
Atomic Force Microscopy – AFM 
All atomic force microscopy was performed in Singapore by Dr Wang Liyang in the labs of 
Prof. Shao Fengwei at Nanyang Technological University. AFM images were obtained on a 
Bruker Multimode 8 SPM equipped with a liquid cell.  
Freshly cleaved mica was treated with 0.1 % (v/v) APTES ((3-Aminopropyl) triethoxysilane) 
aqueous solution for 10 mins to make the surface positively charged, and then washed with 2 
mL ultrapure water and dried by compress nitrogen. 35 uL of DNA tetrahedron (or 
tetrahedron-cylinder conjugate at 1:4) solution was dropped onto the mica surface to 
incubated for 5 min. Then the sample was ready for measurement under the ScanAsyst in 
fluid mode with the SNL-10 probe (Bruker). 
 
UV-Vis Stabalisation 
Two iron cylinder solution of identical concentration (60µM), one alone and one bound to 
DNA tetrahedron at a ratio of 4:1 cylinder to tetrahedron. Samples were incubated in a 1 cm 
path length UV cuvette (Starna) at room temperature for 1 hour before the absorbance of each 
solution was recorded at 573 nm for time point 0. The solutions were then incubated at the 
temperature for the experiment and the absorption recorded at set time points. All UV-vis 
experiments were performed in a Varian Cary 5000 spectrometer and elevated temperature 
runs were also performed in this with a Varian Cary temperature controller. 
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Seperation of the iron cylinder enantiomers 
A slurry of Cellulose powder (Sigma Aldrich – column chromatography grade) (8.00g) and 
0.2M NaCl solution (45 mL) was stirred into a beaker before being added to a 2x40 cm 
sintered glass column. Bellows were used to apply pressure to pack the cellulose in the 
column. Approximately 20 mL of extra 0.2M NaCl solution was added over the next hour to 
ensure the cellulose never went dry during the packing process. Once the cellulose was fully 
packed and the top of the cellulose was exposed. [Fe2L3]
4+ (0.05g) was dissolved in 0.2M 
NaCl solution (0.75 mL). Using a glass pipette, the sample solution was very carefully loaded 
onto the cellulose, ensuring no sample was accidently applied to the sides of the glass. 
Pressure was then applied to push all the sample solution into the cellulose and re-expose the 
top. Approximately 3 cm of sand was then added to protect the top of the cellulose. 0.2 NaCl 
solution can then be freely added to fully eluate the column under pressure. Two purple bands 
could be visibly distinguished and were collected as two separate fractions. The fractions 
were then freeze dried, re-dissolved in methanol and de-salted separately through a G25 
Sephadex column using methanol as the eluent. The samples were then taken to dryness in 
vacuo. Column was repeated until enantiomer samples of sufficient purity were observed by 
CD and chiral shift reagent NMR 
 
Circular Dichroism of enantiomers 
Each enantiomer was dissolved in 50mM Tris.HCl buffer (pH 8.0) to a concentration of 15 
µM as established by UV-Vis at 573 nm (ε=16900) and placed inside a 1 cm path length 
cuvette (starna). A Chirascan plus spectrometer (Applied Photophysics) was then used to scan 
the cuvette using the following parameters; Mode: Circular Dichroism in millidegrees, 
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Bandwidth: 1 nm, Response: 1 secs, Temperature: 25oC, accumulations: 4, Wavelength range 
200-800 nm. Data was collected and the 4 accumulations averaged to provide the presented 
spectra.   
 
 
1H NMR of enantiomers with ∆-TRISPHAT 
Enantiomers M and P along with a racemic mixture were dissolved to a concentration of 500 
µM in MeOD (0.75 mL, Cambridge isotope labs). ∆-TRISPHAT tetrabutylammonium salt 
(sigma) (0.38 mgs) was then added to each sample to produce a molar ratio of 1:1. The NMR 
was run on an AVII-300 300 mHZ NMR. 
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Chapter 3  
 
Biological Activity of the Iron Cylinder-DNA Tetrahedron 
conjugate 
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3.1 Introduction 
The iron cylinder, with its unprecedented DNA binding, differs dramatically from traditional 
DNA binders, such as members of the cisplatin drug family; cisplatin carboplatin, oxaliplatin 
and nedaplatin. These platins are still used today in the clinic despite decades of research in 
the field,1 and it is estimated that between 50-70% of all cancer patients will be treated by 
platinum drugs throughout their therapy.2 For this reason it was interesting to explore the 
biological activity of the iron cylinder; to see whether the promising and very different DNA 
binding would translate to in-vitro cytotoxic effects in cancer cell lines. Research from the 
Hannon group3 showed potent action against a range of cell lines (Table 3.1) with comparable 
IC50 values (concentration of compound required to inhibit cellular growth and viability by 
50%) to those of cisplatin.  
 
 
 
 
 
The research also showed that the iron cylinder was non-genotoxic, meaning that is does not 
cause any DNA strand breaks during its interaction with the cells in a comet assay (Table 
3.2).3 This is important as genotoxic DNA damage, whilst it can contribute to cell apoptosis, 
can also lead to mutations which can then go on to cause cancer,4 which if the original aim 
was to treat the cancer, would be known as secondary cancer and is clearly an undesirable 
attribute in a potential drug. This is the case with  certain current chemotherapy agents such as 
 CELL TYPE: HBL100 
(BREAST) 
T47D 
(BREAST) 
SKOV3 
(OVARIAN) 
HL-60 
(LEUKEMIA) 
MRC5 
(LUNG) 
IRON CYLINDER 
(µM) 
27 ± 5 52 ± 10 35 ± 5 18 ± 3 19 ± 3 
CISPLATIN (µM) 4.9 ±  0.3 28 ± 1.7 6 ± 0.3 7 ± 1 <3 
Table 3.1 - Table from reference 3, showing IC50 values (µM) at 72 hours 
on various cell lines for the Iron cylinder compared with cisplatin. ± SD 
(n=3).  
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cisplatin5 and gemcitabine (a cytidine analogue).6 Overall, the iron cylinder was shown to 
have very interesting biological activity. 
IRON CYLINDER 
(µM) 
MRC5 
(LUNG) 
HBL100 
(BREAST) 
HL-60 
(LEUKEMIA) 
0 1.43 ± 0.82 4.89 ± 3.84 0.27 ± 0.15 
5 2.18 ± 0.12 8.93 ± 4.07 0.40 ± 0.51 
10 2.54 ± 0.47 6.16 ± 4.41 0.39 ± 0.47 
15 2.31 ± 0.57 6.29 ± 4.17 0.45 ± 0.39 
20 1.86 ± 0.44 6.48 ± 2.46 1.95 ± 2.33 
25 2.32 ± 0.22 ND ND 
 
 
 
 
The previous chapter focussed on the interaction between the iron cylinder and DNA 
tetrahedron. The tetrahedron itself has also been reported to have interesting biological 
properties in that it is readily taken up by cells.7 This led to proposals suggesting that the 
DNA tetrahedron could be used for drug delivery applications due to its hollow central cavity 
able to hold a cargo, such as the protein cytochrome c (Figure 3.1A),8 or a single transcription 
protein (figure 3.1B).9 Successful drug delivery of doxorubicin has been reported with the 
DNA tetrahedron,10 which was reported to overcome drug resistance due to an altered uptake 
mechanism which meant developed cellular metabolism resistance was by-passed. With these 
interesting biological properties, it would be interesting to study the combined biological 
effects of the cylinder-tetrahedron conjugate. 
 
 
Table 3.2 - Table from reference 3. The results represent tail DNA % ± SD (n = 3) of 
three independent experiments. There was no statistically significant effect of cylinder 
treatment (24 hr) at any of the concentrations investigated in any cell line studied. ND, 
not determined because 25 μM, 24 hr was toxic to these cell lines. 
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This chapter aims to study the tetrahedron cellular uptake, localisation and toxicity of the 
cylinder conjugate. The chapter aims to also pave the way for further research using the 
cylinder binding effect of collapsing the tetrahedron into a smaller structure for triggering the 
release of an internal cargo by proving the compatibility of the conjugate inside cells.     
 
3.2 Results and Discussion 
3.2.1 Cellular Uptake 
The iron cylinder enters cells readily11 to exhibit strong cytotoxic effects across a broad range 
of cell lines.3 It is interesting to explore whether the iron cylinder, when bound to the DNA 
tetrahedron, would still be taken up by cells and whether this uptake would be altered in any 
way from previous reports of tetrahedron uptake. It would also be interesting to see any 
changes in the effect of the cylinder on the cells when delivered by the DNA tetrahedron. To 
study this, the conjugate and the tetrahedron alone were subjected to various in-vitro 
A B 
Figure 3.1 - A: DNA tetrahedron containing the protein cytochrome c, covalently 
bound to the inner cavity. B: catabolite activator protein (CAP) encapsulated non-
covalently by using a DNA recognition site for the protein to bind to. A taken from 
reference 8, B taken from reference 9. 
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experiments on cancer cell lines to determine the behaviour of each and if they differ in any 
way.  
3.2.2 Flow Cytometry 
One commonly used technique to observe cellular uptake of a drug is by flow cytometry. For 
this technique, the drug must be fluorescent for it to be observed inside the cell. The technique 
itself involves passing a suspension of cells through an electronic cell counter one by one, 
which excites each cell with a laser at a chosen wavelength so that the emission intensity of 
the fluorescent complex inside each counted cell can be recorded. This effectively and 
efficiently produces data on how many treated cells have taken up the analyte. The machine 
can then go on to sort the cells based on their fluorescent output. Figure 3.2 shows a 
schematic diagram of a flow cytometer in action.12 
 
 
 
 
  
 
 
 
 
Figure 3.2 – Schematic diagram representing a flow cytometer exciting 
fluorescently tagged cells via an external light source. Taken from reference 
12. 
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To utilise flow cytometry for cellular uptake, the conjugate would first have to be made 
fluorescent for it to be observable by the detector. Due to the ease of functionality of DNA, 
this was achieved by purchasing one of the construction strands of the tetrahedron, labelled 
with Cyanine-5 (Cy5). Cy5 is a fluorescent dye which emits in the far red end of the spectrum 
with an emission maximum at 666 nm. The tetrahedron can then be synthesised as before to 
form a Cy5 labelled tetrahedron, following a previously reported method.7  
Three samples of HeLa cells were then incubated with the cylinder, labelled tetrahedron, and 
with the labelled tetrahedron - cylinder conjugate for 24 hours and analysed using flow 
cytometry. Figure 3.3 shows the cellular uptake with and without the presence of the cylinder 
on the tetrahedron by measuring the Cy5 emission of each cell at 670 nm. Three identical 
separate repeats of this experiment were performed, counting 10,000 cells in each sample 
cycle. The forward and side scatter of a control sample of HeLa cells in each repeat 
experiment was manually gated and this gate applied to all subsequent fluorescent 
measurements of that repeat set to remove any dead cells or large material that will pass 
through the flow cytometer that should not be included in the data interpretation as they 
cannot be considered viable cells.  
From this, it can be seen that the uptake of the tetrahedron over 24 hours is extensive with 
94% of the gated cells emitting a Cy5 signal when treated with the Cy5 tetrahedron. 95% of 
cells emitted a Cy5 signal when treated with the Cy5-conjugate, showing there is no 
statistically significant difference between the two. Both the no treatment control and the cells 
treated with just cylinder resulted in a very low amount of emission in this window, which is 
expected and has been attributed to auto-fluorescence from the cell.   Interestingly, the uptake 
is almost identical for the tetrahedron with or without the cylinder bound to it. It might have 
been anticipated that the positively charged cylinder would negate some of the negative 
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charge on the DNA and help the conjugate pass through the negatively charged cell 
membrane. This is not the case, however, initially suggesting that the tetrahedron is actively 
up-taken through endocytosis as previously proposed, as it seems unlikely that this amount of 
tetrahedron would be able to enter the cells by passive diffusion due to the negative charge on 
DNA with is consistent with previous research.13 The intensity of the Cy5 peak of the 
histograms of the treated cells is also very similar. This suggests that roughly an equal amount 
of the tetrahedra are taken up, regardless of cylinder presence. Whilst this experiment shows a 
good indicator of overall cellular uptake, it does not give any idea of cellular localisation.  
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Figure 3.3 - Flow cytometry data, left column showing dot plots of the samples with gated 
control at the top. Middle column – histogram distributions of Cy5 intensity. Right – 
Overlap of sample Cy5 intensity and non-treated control sample.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CY5 POSITIVE: % 
CONTROL 17.0  
CYLINDER 13.0  
CY5-TETRAHEDRON 93.7  
CY5-CONJUGATE 94.8  
Control 
Cylinder
 
 Control 
Cy5-Tet
 Control 
Cy5-Conjugate
 
 Control 
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3.2.3 Confocal Microscopy 
Exploiting the Cy5 label on the tetrahedron again, fluorescence microscopy can be a very 
powerful tool in analysing cellular localisation of a substance. Confocal microscopy works by 
exciting the sample with lasers of a chosen wavelength. A pinhole in the focal plane of the 
light then filters out the out of focus light, only allowing the image of the current level of 
focus through to the detector. This allows the user to build up a 3D profile of the analyte by 
taking snapshots of each level. This can be hugely effective for analysing localised cellular 
uptake of fluorescently tagged molecules and compounds. 
In this experiment, HeLa cells were incubated with a relatively low concentration of Cy5-
conjugate (2µM, 1:4 tetrahedron (2µM) : cylinder (8µM)) for time periods of 2 hours and 24 
hours. The HeLa cells were then stained with Hoechst nuclear stain, staining the nucleus of 
the cells blue for visual reference and to help establish localisation of the Cy5. The cells were 
then fixed onto slides and imaged on a Nikon A1 inverted confocal microscope. Figure 3.4 
shows the images obtained.  
 
 
 
 
 
 
 
Figure 3.4 - Confocal fixed cell imaging showing cell uptake of Cy5-Conjugate after 2 
hours (left) and 24 hours (right). 
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From this, it is clear to see that even after just 2 hours of incubation, the labelled conjugate is 
taken up into cells. This backs up previous analysis with flow cytometry that the conjugate is 
taken up by cells. Accumulation does appear to increase with time but only slightly and not in 
a linear fashion and further quantification of the fluorescent images would be needed to 
confirm this.  
Attempting to distinguish localisation of the conjugate inside the cells from these images was 
challenging as it appears to be in some cell nuclei but not in others. To attempt to assess this, 
live cell imaging was performed to analyse localisation in cells in their natural state. Live cell 
imaging is useful here since fixing cells with formaldehyde could lead to analyte compound 
leaching through breached membranes that have become so during fixation, causing 
uncertainty as to original accumulation and localisation. 
Cells were incubated in 3 cm Matek dishes with compound incubation times kept at 3 hours 
for all samples. Figure 3.5 shows the results obtained. By staining the cells with Hoechst 
nuclear stain, it was hoped that the degree of localisation in the nucleus could be quantified by 
a co-localisation calculation. However, the conjugate mainly accumulates in the cytoplasm 
and doesn’t appear to be in specific areas here. Figure 3.5 is also in agreement with the 
previous flow cytometry experiment showing the uptake is largely unaffected whether the 
cylinder is present on the tetrahedron or not. To ascertain the localisation by confocal 
microscopy, further experimentation with different structural stains to see if significant co-
localisation could be seen.  
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Another advantage of confocal microscopy is the ability to build up a 3D image of the cells. 
As the focal plane can be adjusted throughout a cell, images can be taken for each slice. This 
Figure 3.5 – Confocal image montages, Left, HeLa cells incubated with [Fe2L3]Cl4 (8 µM) and 
stained with Hoechst 33258 to visualise the blue nucleus. Centre, HeLa cells incubated with Cy5-
Tetrahedron (2 µM) and stained again with Hoechst. Right, HeLa cells incubated with Cy5-
Conjugate (4:1 cylinders to tetrahedron corresponding to 8 µM : 2 µM). 
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helps to illustrate the complex is not simply accumulating on-top of the cell membrane instead 
of inside the cell. Combining the slices produces a Z-stack which builds up a 3D profile. 
Figure 3.6 illustrates this, presenting Cy5 signal throughout the cell and confirming complex 
presence inside the cell.  
 
 
 
 
 
 
 
 
3.2.4 ICP-MS analysis 
A further useful technique that can be utilised to ascertain cellular localisation is inductively 
coupled plasma mass spectrometry (ICP-MS). This technique is a quantitative variation of 
mass spectrometry which involves atomising a sample using an inductively coupled plasma 
created with Argon gas. The ionised sample is then separated into elements using quadrupoles 
and quantified in a connected mass spectrometer. This technique is highly sensitive and can 
detect elements (mainly metals) in a sample down to ppb quantities.14  
This technique is useful as biological samples can be digested and analysed by ICP-MS. By 
separating the major structures of cellular samples, a process known as cell fractionation, it is 
Figure 3.6 – Z-stack images combined to produce a 3D image showing red Cy5 inside the 
cell. Left – Front on view. Right – Side on view. 
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possible to analyse each fraction for presence of certain analyte metal ions and quantify them. 
Through this, it would be possible to quantify and compare cellular accumulation in the 
nucleus and the cytoplasm of the cell. Unfortunately, the presence of natural iron inside cells 
prevents quantitative iron analysis here, as it gives too high a background reading for accurate 
measurement. To get around this, the central metal ions in the cylinder need to be replaced. If 
the new cylinder binds in a similar fashion to the DNA tetrahedron, it could provide a similar 
model for cell accumulation that could be quantified with ICP-MS.  
A cylinder with the same ligand structure, shape and size but with two ruthenium(II) ions in 
place of the iron was reported in the Hannon group in 2007.15 Figure 3.7 shows the crystal 
structure obtained of the iron cylinder and the ruthenium cylinders (RuCy), illustrating the 
close-to-identical size and shape of the two molecules.15,16,17  
 
 
 
 
 
 
 
 
 
Figure 3.7 - A – The ligand (L) in the cylinders. B – Crystal structure of the iron cylinder 
[Fe2L3]4+ and C – Crystal structure of the ruthenium cylinder [Ru2L3]4+, Taken from 
reference 15. 
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The RuCy also shows very similar binding to the iron cylinder to DNA, causing supercoiling 
in linearized plasmid DNA.15 To show the RuCy has similar binding to the tetrahedron and its 
building blocks, a PAGE gel was carried out, running iron cylinder with DNA tetrahedron 
building strands next to ruthenium cylinder and building strands. Figure 3.8 shows identical 
band shifts between the iron and the ruthenium, illustrating that the similar size and shape of 
the complexes shown by x-ray crystallography translates to similar binding to the tetrahedron. 
This indicates that the conjugates should be similar and therefore cylinder uptake into cells 
might be quantified by ICP-MS, scanning for ruthenium content. 
 
 
 
 
 
 
 
 
  
 
 
 
Fe   Ru 
Fe  Ru 
Fe  Ru 
Fe   Ru 
1 
2 
3 
4 
Figure 3.8 – Autoradiogram showing the building blocks of the DNA tetrahedron: lane 1 
– strand 1 only, lane 2 – strands 1+2, lane 3 – strand 1+2+3, lane 4 – complete 
tetrahedron. Adjacent to each numbered lane is identical DNA incubated with iron or 
ruthenium cylinder as indicated. 
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HeLa cells were incubated with RuCy and RuCy-conjugate, followed by fractionation of the 
cells into nuclear and cytoplasmic fractions. ICP-MS was then use to ascertain the levels of 
ruthenium metal in each of the fractions and also be compared to a whole cell sample 
gathered. Figure 3.9 shows the results obtained from this ICP-MS experiment. The control 
cells show the base level of no ruthenium atoms detected in all fractions (a background). The 
cells treated with RuCy alone showed a positive amount of ruthenium in the whole cell 
fraction. It also showed that around a third of the RuCy is accumulated in the nuclear fraction 
whilst the rest is found in the cytoplasm. These results are encouraging as it shows that some 
of the cylinder is able to pass into the nucleus, the target for DNA binding drugs. The cells 
treated by the RuCy-tetrahedron conjugate showed a dramatic increase in Ruthenium content 
in the whole cell sample. This was a very positive result as it suggests that the cells, when 
actively up taking the tetrahedron, do so more effectively than the RuCy up take alone. This 
further champions the tetrahedrons case as a drug delivery vessel.  
 
 
 
 
 
 
 
 
Figure 3.9 – ICP-MS data presenting Ruthenium content accumulated in whole 
cell, nuclear and cytoplasmic fractions when HeLa cells have been treated with 
Ruthenium cylinder with and with DNA tetrahedron. 
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Figure 3.9 also shows the nuclear accumulation is also increased by 75% from approximately 
20 pmole/ 106 cells to approximately 35 pmole/ 106 cells. This must again be down to 
differing cellular uptake pathways and cell metabolism of the conjugate. A slightly 
unexpected result came from the cytoplasmic fraction which showed a decrease from the 
RuCy alone. This meant that the combined nuclear and cytoplasmic ruthenium content did not 
equal the whole cell sample. It could be suggested that the remaining ruthenium remains on 
the membrane of the cell, which would be in agreement with the endocytosis uptake of the 
conjugate as some would still be stuck on the membrane in this case. Further repeats of this 
experiment and analysis of the membrane fraction are required to fully come to this 
conclusion.  
3.2.5 Cell Toxicity – MTT Assay 
As discussed in the introduction, the cytotoxicity of the iron cylinder has been studied in 
depth.3 Now that the cellular uptake of the cylinder-tetrahedron conjugate has been studied, it 
is important to see whether the cylinder’s toxicity is maintained when delivered by 
tetrahedron. It is possible, as observed by other research groups, that the uptake mechanism 
can alter drug localisation and therefore cause an altered toxicity effect.10 To study this, a very 
commonly used cell viability assay known as an MTT assay was employed. An MTT assay 
works by treating cells, post drug treatment, with a tetrazolium dye MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Figure 12). The MTT salt, when 
inside the cell is reduced by NAD(P)H dependant oxidoreductase enzymes, located in cell 
mitochondria, to insoluble formazan (Figure 3.10). This formazan is deep purple in colour 
which is then dissolved in DMSO to produce a quantifiable purple solution that is then read 
by a spectrophotometer / plate reader.18 This gives an indication of cell viability as more cells 
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produce more formazan which gives a higher absorption reading on the plate reader and vice-
versa. This assay also allows for the calculation of the IC50 value.   
 
 
 
 
 
 
 
It is worth noting that there can be some doubt about the effectiveness of the MTT assay as a 
tool for assessing cell death. This is mainly because low mitochondrial activity doesn’t 
necessarily confirm cell death; some cell lines exhibit low metabolism and thus low levels of 
mitochondrial activity and so would appear as ‘non-viable’ in the assay. In this case however, 
the control cells give a comparative reference of activity to the treated cells and the cell lines 
have been selected to ensure that the cell metabolism is high enough to be accurately 
measured in this assay.  
Two cell lines were selected, HeLa, a cervical cancer cell line used throughout this chapter, 
and A2780, an ovarian cancer cell line; these cells were then treated with increasing 
concentrations of free cylinder and cylinder-tetrahedron conjugate. Cisplatin was also 
included in the treatments as a positive control as it is still considered to be the ‘gold-
standard’ of chemotherapy drugs in use today.  
Figure 3.10 - Reaction scheme illustrating the reduction of MTT to form purple formazan. 
Taken from reference 18. 
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Figure 3.11 shows the results obtained. In both cell lines, it is clear that the conjugate has a 
diminished toxicity when compared to free cylinder, though this is more dramatic in A2780 
cells than in HeLa cells. This was not a totally surprising result as the cylinder is bound to 
DNA when on the tetrahedron, and so cellular DNA will have to compete with the tetrahedron 
for cylinder binding. This therefore means that less overall cylinder will be immediately 
available to bind to cellular DNA and cause apoptosis. Overall, the conjugate still maintained 
a potent amount of cell toxicity. 
It is assumed that the cylinder, when bound to the tetrahedron, simply preferentially binds to 
cellular DNA due to its abundance. However, another hypothesis could be that the cylinder is 
not released to bind to genomic DNA until the tetrahedron is digested inside the cells. To test 
this, a tetrahedron was synthesised which was less susceptible to digestion. The full details of 
this will be discussed in chapter 4, but follows a previously reported protocol by Goodman et 
al.19 Briefly, it involves phosphorylating all the construction oligos and ligating them together 
to form a tetrahedron with no nicks in the backbone. This makes it more resistant to digestion 
as many cellular enzymes can only initiate on the 5’ or 3’ end of DNA or DNA blunt ends.20 
As the ligated tetrahedron would have none, this should make it more resistant to digestion 
once inside the cell. If cell toxicity was further decreased when the cylinder was delivered by 
the ligated tetrahedron, it would indicate that cylinder is being released upon digestion of the 
tetrahedron and it is not delivered simply by shifting to a more preferential target amongst the 
cellular DNA. Figure 3.12 shows the MTT assay obtained when treating with the same 
cylinder concentration (25 µM) delivered by the original nicked tetrahedron and with the 
ligated un-nicked tetrahedron. From this, it can be seen that the cell viability post-treatment of 
both is identical and therefore cellular digestion of the tetrahedron is unlikely to be the 
mechanism of drug delivery in this case.    
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  HELA A2780 
IRON CYLINDER 37 ± 3 4.3 ± 0.7 
CISPLATIN 5.6 ± 0.8 1.2 ± 0.3 
CONJUGATE 39.7 ± 4.4 10.8 ± 2.4 
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Figure 3.11 - MTT assay results from 72 hours of indicated drug concentration treatment. Top 
– A2780 cell line, Bottom – HeLa cell line, table below presenting IC50 values in µM. Error 
bars correspond to the standard error of the mean result of n=3 repeats 
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3.3 Conclusions 
This chapter set out to investigate the potential biological compatibility of the DNA 
tetrahedron as a drug delivery vessel. By testing the cellular uptake through various means, it 
can be concluded that the tetrahedron is very compatible and is readily taken up by cancer 
cells in an in vitro environment. It is also shown that both the iron cylinder and the ruthenium 
cylinder could be delivered by the tetrahedron to cells. Once delivered, it was shown that the 
toxicity of the iron cylinder was maintained, although at a diminished level. Although ICP-
MS studies gave insight as to where the cylinders end up once delivered to cells, further 
experimentation is needed to fully ascertain the localisation of the tetrahedron in the cell, for 
example, by staining alternative cell structures to find co-localisation in a confocal 
microscopy experiment.  
Figure 3.12 – MTT assay comparing toxicity of 25 µM of cylinder when delivered by 
ligated tetrahedron and un-ligated tetrahedron with free cylinder as a positive control.  
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The question of whether the conjugate remains intact when entering the cell or whether the 
cylinder separates before uptake is a pertinent one. For this question to be answered, it must 
first be possible to visualise the cylinder inside the cell. Currently the Hannon group is still 
attempting to synthesise a cylinder possessing a fluorescent tag which would enable 
simultaneous visualisation of the cylinder and the tetrahedron inside the cell, allowing FRET 
studies to be carried out. This would be crucial to understanding the state of the conjugate at 
this stage. Unfortunately, this continues to be a very challenging goal. However, evidence of 
increased cylinder uptake when delivered by tetrahedron and diminished toxicity both point 
strongly to the fact that the conjugate is initially intact inside the cell.    
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3.4 Experimental  
Materials: Enzymes T4 Ligase and Kinase were purchased from New England Biolabs. All 
chemicals were purchased from Sigma Aldrich unless otherwise stated. DNA oligonucleotides 
were purchased HPLC purified from Eurofins. DMEM medium (high glucose) was purchased 
from sigma. RPMI medium was purchased from life technologies. Cell culture equipment was 
purchased from Corning.  
 
Flow Cytometry: HeLa cells were seeded into a 24-well plate at 35,000 cells per well, 
counted using a Haemocytometer. Cells were supplemented with DMEM medium (1ml) and 
left to incubate in the wells for 48 hours at 37oC to allow them to adhere fully to the well. 
Leaving control wells, separate wells were treated with cylinder alone, Cy5-Tetrahedron and 
Cy5-Conjugate to final concentrations of  20 µM of cylinder and 10 µM of DNA tetrahedron, 
corresponding to a ratio of 2:1 cylinder : tetrahedron in the Cy5-Conjugate sample well 
(400µl). Samples were then incubated overnight. Samples were then trypsinised (5mins) and 
re-suspended in PBS solution (2ml). They were then added to separate FACS tubes and each 
sample run on a BD FACscaliber flow cytometer with a Cy5 excitation laser. For each sample 
10,000 cells were counted for a total of three repeat experiments.  
 
Fixed Cell Confocal imaging: HeLa cells were seeded at 50,000 cells per well inside a 24 
well plate containing a sterilised glass coverslip and supplemented with DMEM. Cells were 
left to adhere to coverslip for 24 hours. Cells were then incubated with Cy5 containing 
compounds (5 µM) for either 2 or 24 hours. Media was then aspirated and cells washed with 
thoroughly with PBS solution to remove any non-internalised compound. Cells were then 
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stained with Hoechst 33258 in DMEM (25 µg/mL) (500µl) for 30 min. The solution was 
again aspirated and cells washed 3 times with PBS (3 x 300 µL per well) and 4% formalin 
solution (500µl) was then added and left for 10 min. The formalin solution was then removed 
via pipette and cells washed with PBS (2 x 300 µl). The Glass coverslips were then removed 
from the wells, using a needle tip and tweezers, and washed in a PBS bath followed by a pure 
water bath by dipping. Coverslips were then placed face down onto a microscope slide which 
had been spotted with oil. The slide was then imaged on a Nikon A1 confocal microscope.  
    
Live Cell Confocal imaging: HeLa cells were seeded into Matek dishes at 300,000 cells per 
dish as counted with a Haemocytometer, and left to incubate at 37oC for 48 hours in DMEM 
media (3ml) to allow them to adhere fully to the cover slip. Media was then removed and the 
cells washed with PBS (5ml). The cells were then treated with cylinder / Cy5 labelled DNA to 
a final concentration of 8 µM of cylinder and 2 µM of Cy5-Tetrahedron, corresponding to a 
ratio of 4:1 cylinder : tetrahedron in the Cy5-Conjugate sample well (1ml). The dishes were 
incubated for pre-determined times before the solutions were aspirated and the cells washed 
thoroughly with PBS (3 x 5 ml). The cells were then stained with Hoechst 33258 nuclear stain 
by incubating the cells with 2mL of 25µg/mL Hoechst in DMEM media for 30 mins. The 
stain was aspirated and cells washed again with PBS (3 x 5 ml). Clear imaging medium (life 
technologies) was then added to the dishes and the cells imaged on a Nikon-A1 confocal 
microscope. 
 
Cell Toxicity Assay – MTT Assay: Cells of cell lines A2780 or HeLa were seeded into 96 
well plates at 13,000 cells per well as counted by a Haemocytometer and left overnight in 100 
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µL per well of RPMI (A2780) or DMEM (HeLA) media to adhere and settle in the plate. 50 
µL of compound solutions were added to each well to achieve treatment final concentrations. 
All wells in both plates were then topped up to a final volume of 200 µL with DMEM/RPMI 
media. The plates were then incubated for 72 hours. After incubation, all media was removed 
by pipette and each well washed with PBS solution (2 x 200 µl). 180 µL of DMEM/RPMI 
media was added to each well followed by 20 µL of MTT solution (7.5 mg in 1.5 mL) and 
mixed well by pipette. The plate was then incubated for 2 hours and then all media removed 
from the wells via pipette. 200 µL of DMSO was added to each well and incubated for a 
further 30 minutes. After being placed on a rocker for 5 minutes, the absorbance at 570nm of 
each well was recorded on a Tecan infinite F200 PRO plate reader. Each concentration was 
replicated in 4 wells on the same plate and each full experiment was repeated separately 3 
times (n=3) 
 
Synthesis of Parent Ligand (L: C25H20N4) 
4,4’Methylenedianiline (1.99g, 0.01 mol) was dissolved in ethanol (10 ml). To this solution, 
pyridine-2-carboaldehyde (1.90 ml, 0.02 mol) was added. The solution was then left to stir 
overnight. The yellow precipitate formed was then collected by vacuum filtration. The crude 
product was then purified by re-crystallisation from ethanol (3.50 g, 93% yield). The product 
is a pale yellow solid.  
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Mass Spectrum (ESI): m/z = 399 {M+Na} 
1H NMR (300 MHz), CDCl3, 298K: δ 8.71 (2H, d, J = 3.9 Hz, 6py), δ 8.63 (2H, s, J = Him), δ 
8.22 (2H, d, J = 7.0 Hz 3py), δ 7.82 (2H, td, J = 8.3, 1.9, 0.6 Hz, 4py), δ 7.40 (2H, ddd, J = 
7.6, 4.9, 1.2 Hz, 5py), δ 7.30 (8H, m, Pha and Phb), δ 4.08 (2H, s, CH2) 
 
Synthesis of Ruthenium Cylinder, [Ru2(L)3](PF6)4: RuCl3 (3g, 14.5 mmol) was dissolved 
in 15 mL of DMSO and heated under reflux at 195oC for 5 minutes. The solution was reduced 
in vacuo to concentrate the solution down to 1 mL. Excess cold acetone was then added to 
precipitate a yellow solid. The yellow precipitate was then filtered and washed with cold 
acetone to furnish the yellow solid Ru(DMSO)4Cl2.  
Ru(DMSO)4Cl2 (0.988 g, 2.04 mmol) and parent ligand (1.150 g, 3.06 mmol) were added to 
degassed Ethylene glycol (50 ml) and heated to reflux under argon at 200oC for 5 days. The 
mixture was allowed to cool and an excess saturated methanolic solution of ammonium 
hexaflourophosphate was added. The suspension was cooled on ice before the precipitate was 
filtered and washed with methanol (2 x 40 ml) and dried with ether (3 x 100 ml). The dark 
brown product was purified by column chromatography on alumina using 20:1:1 MeCN/H2O/ 
KNO3(aq) solution as eluent to yield the product as an orange solid (11 mg, 0.6% yield).  
Mass Spectrum Positive ion ESI: m/z = 666 [M-(PF6)4]
2+, 444 [M-(PF6)]
3+ , 333.2 [M-(PF6)
4+ 
1H NMR (300MHz), CD3CN, 298K : δ = 8.7 (2H, s, Him), 8.45 (2H, d, J = 7.6 Hz, 6py), 8.35 
(2H, td, J = 7.78 Hz, 5.0 Hz, 3py), 7.65 (2H, d, J = 6.0 Hz, 4py), 7.65 (2H, d, J = 6.0 Hz, 5py), 
7.0 (4H, d, J = 8.4 Hz, Pha/b), 5.7 (4H, d, J = 8.3 Hz, Pha/b), 4.1 (2H, s, CH2) 
UV-Vis (CH3CN) : λmax   (ε / dm3 mol-1 cm-1)  485 (24200)  
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ICP-MS Cell uptake analysis: 3 separate T75 flasks were seeded with HeLa cells and 
incubated in DMEM media until fully confluent. Medium was aspirated from the flasks and 
the cells washed with PBS. To one flask was added 5 mL of medium, to be used as a control. 
To another, 5 mL of medium containing 2 µM final concentration of Ru cylinder was added 
and to the final 5 mL of medium containing 4:1 Ru cylinder – Tetrahedron conjugate (0.5 µM 
: 2 µM) final concentration was added. The flasks were left to incubate for 24 hours at 37oC 
before the cells were collected and pelleted. Two samples of 2 million cells were taken from 
each pellet. One sample was then fractionated into a nuclear fraction and a cytoplasmic 
fraction whilst the other was kept as a whole cell sample. The fractionation procedure was 
carried out using a Nuclear/Cytosol fractionating kit (BioVision) following the provided 
protocol. All samples were then digested using 500 µL concentrated ultra-pure HNO3 (Fluka) 
at 80oC for 16 hrs in glass vials. Samples were diluted to 5% HNO3 solution with ultra-pure 
water to 5 ml and analysed. The Ruthenium content of each sample was then analysed on an 
Agilent 7500CX ICP-MS. 
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Chapter 4:  
 
DNA Photocleavage with a Ruthenium Cylinder 
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B A 
Figure 4.1 – A) Structure of [Ru(bpy)3]2+ (taken from 8), B – Structure of  [Ru(bpy)2(dppz)]2+. 
Taken from ref 5. 
4.1 Introduction 
Ruthenium complexes capable of inducing DNA photocleavage have been studied extensively 
over recent years with the main examples centred around [Ru(bpy)3]2+ (figure 4.1a).1 The 
interest in ruthenium complexes in regard to DNA photocleavage is due to their extensive and 
variable photophysical, photochemical, and redox properties.2 Ru(II) DNA photocleavage 
agents must first be able to bind to DNA to provide a platform for the various energy transfer 
mechanisms that lead to photocleavage. Various ligand choices can lead to differing binding 
modes or structural preferences, with intercalation a popular choice, notably the DNA ‘light 
switch’ molecule [Ru(bpy)2(dppz)]2+ (figure 4.1b) which revolutionised research in this area.3 
In recent times binding to DNA from these octahedral Ru(II) complexes is agreed to be a 
combination of electrostatic interactions between the positive complexes and the negatively 
charged phosphosugar backbone of DNA4, surface binding into the major / minor grooves in 
the DNA5, along with the fore-mentioned ligand intercalations. 6 3 
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A B 
Figure 4.2 – A)  Structure of HAT,  B) – Structure of TAP. (Image taken from ref 11). 
Photocleavage agents also need to possess certain photophysical properties to facilitate the 
cleavage. In Ru(II) complexes, this usually involves having a 3MLCT excited state as a 
platform for energy transfer. Cleavage can then progress through production of a singlet 
oxygen excited state (1O2), which is generated by exciting an election to the lowest-lying 
triplet excited state in the 3MLCT state which then transfers energy to the 3O2  ground state to 
produce 1O2.7  
Another similar photocleavage pathway follows the same initial excitation to the 3MLCT, but 
this then transfers an electron to O2 to form a superoxide anion (O2-) which can react with 
water to from a hydroxyl radical (.OH).8 This hydroxyl radical can then go on to cleave DNA 
through a nucleophilic addition-elimination on the DNA phosphosugar backbone. Both of 
these mechanism pathways require the presence of O2 to proceed. 
Alternatively, some reported Ru(II) complexes have been designed to cleave in a completely 
different fashion, by incorporating electron deficient ligands with Ru(II) (Figure 4.2) which 
can directly abstract DNA base electrons into their deficient 3MLCT state and cause cleavage 
through that fashion.9 Two example ligands which proceed through this mechanism9 when 
complexed to Ru(II) are tap (1,4,5,8-tetraazaphenanthrene) and hat (1,4,5,8,9,12-
143 
 
hexaazatriphenylene) (figure 4.2a and b).10  
In a similar mechanism, Ru(II) complexes have also been synthesised that can be oxidised to 
Ru(III) through photo irradiation. These highly oxidising Ru(III) species can then abstract 
electrons from the DNA bases to induce cleavage.11,12 These last two mentioned mechanisms 
differ from the earlier two as they are considered to be anaerobic and do not require the 
presence of O2. This has been considered an advantage in certain applications such as 
photodynamic therapy for treating cancer as tumours in general terms are considered to be 
quite hypoxic, lacking oxygen due to sporadic blood circulation. 
 
One of the main applications of these DNA photocleavage agents has been for use in treating 
cancer with photodynamic therapy (PDT).13 PDT involves first treating the patient with a 
photosensitizer drug which can then locate to the sites of a tumour. The drug in this case is 
usually inactive and non-toxic at this stage.14 Light can then be shone on the tumour site, 
Figure 4.4 - Schematic diagram illustrating anaerobic DNA photocleavage 
through a Ru(III) intermediate. Taken from ref 12   
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exciting the complex and beginning the DNA damage mechanisms which can lead to various 
cell death pathways. These are usually from cellular apoptosis from DNA damage, damaging 
blood vessels around the tumour which resists blood supply, and more recently thought to 
activate some immune responses.15 
Currently the only photosensitizer drug licensed in the clinic for treatment of internal cancers 
is Photofrin® , also known as Porfimer sodium16 (Figure 4.4). After administration, Photofrin 
is excited by a strong red laser at 630 nm internally using a fibre optic probe. It is currently 
used to treat bladder, oesophageal and non-small cell lung cancers.17 Limitations of PDT, 
disregarding the usual adverse side effects experiences by most forms of chemotherapy, 
include treatment area being limited to areas which can be accessed by the laser probe. Also, 
as the drug requires strong laser excitation, tissue damage directly from the laser is common. 
The depth at which the laser can penetrate through tissue and maintain the level of energy 
required to initiate 1O2 production can also be limited depending on the tissue involved.17, 18 
Figure 4.4 - Structure of Photofrin® taken from 18. 
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Our group reported that the ruthenium cylinder had the capability to photocleave DNA.19 
Following on from the previous chapters, detailing cylinder binding to the DNA tetrahedron, 
this chapter aims to explore the photocleavage capabilities further. By applying it in context to 
the DNA tetrahedron, it was hoped to take a different angle on possible applications of PDT 
by ‘breaking open’ a DNA nanostructure with an external light trigger (Figure 4.5). This 
would be done with a view to release a possible internalised cargo and the first time DNA 
nanotechnology and a photosensitizer of this sort are combined in this application.   
 
 
 
 
 
 
 
 
4.2 Results and Discussion 
4.2.1 Plasmid Photocleavage 
Firstly, to establish the conditions of photocleavage, a positive control experiment was. As 
discussed, the ruthenium cylinder has proven capable of DNA photocleavage19, although not 
Figure 4.5 - Illustration of utilising photo-cleavage to break apart a DNA tetrahedron 
Light Irradiation 
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in conjunction with DNA nanostructures or with the low powered LED bulbs planned for this 
experiment. Tracking DNA plasmid photocleavage with agarose gel electrophoresis provides 
a very clear and quantifiable result that has been used in many publications over the years.20 
This is because it provides a very clear indication of positive photocleavage with a large band 
shift and also gives indication of the nature of photocleavage – whether a single or double 
strand break has occurred.21 Figure 4.6 shows a typical agarose gel result obtained, illustrating 
both when a single strand cleavage has occurred, and when a double stand cleavage occurs.  
 
 
 
 
 
 
 
 
 
With a positive control experiment proposed, the plasmid pUC19 was used for the 
experiments. This plasmid is readily available and tends to produce sharp clear bands in gel 
electrophoresis with the majority of the plasmid in the natural supercoiled form as desired 
here. Figure 4.7 shows PuC19 run after being deliberately damaged with a strong UV light for 
Figure 4.6 - Agarose gel showing a pBR322 plasmid band in its natural supercoiled form and 
with cleavage to form non-coiled (single strand break) and linear plasmid (double strand 
break).Taken and illustrated from 21 
Super-coiled Plasmid 
‘Nicked’ open coiled 
Plasmid 
Linear Plasmid 
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10 mins to initiate strand cleavage. This was done to establish where the cleavage band would 
migrate in relation to the DNA ladder used.  
 
It is desirable for the ruthenium cylinder to photocleave DNA using low power LED bulbs 
that produced minimal heat. This is because a low level light would maximise possible 
medical applications - high powered lasers and bulbs can cause tissue damage in  
 
phototherapy applications. To begin the experiments, a 1W white LED bulb was used. This 
would give a broad range of emission for the ruthenium to absorb from and thus transfer 
energy to initiate the photocleavage mechanism. Figure 4.8 shows the agarose gel of pUC19 
2 KB 
1.5 KB 
3 KB 
   1               2 
Figure 4.7 - 1% Agarose gel run in 1 x TAE Buffer. Left lane - reference DNA ladder, Lane 1 
– pUC19 plasmid unchanged, Lane 2 – pUC19 treated with 10 minutes to UV light to initiate 
strand breakage to a linear form. 
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Figure 4.9 - UV-Vis absorption spectrum of the RuCy. 
plasmid. From this gel, it is clear that over the 10 hour period of the experiment; only a small 
amount of strand breakage was detected. At 10 hours, still 55% of the plasmid remains in the 
unbroken supercoiled state. The majority of the cleavage was single stranded with 35% of the 
Figure 4.8 - 1% Agarose gel run in 1 x TAE Buffer. Lanes 1 and 9 – control containing pUC19 
plasmid. Lane 2 – Plasmid under 24 hours of illumination (1W, white light). Lane 3 – Plasmid 
with RuCy (100 bp:1 RuCy) with no illumination. Lanes 4-8 – Plasmid with Rucy with 2, 4, 6, 8 
and 10 hours 1W white light illumination respectively. 
  1            2            3            4             5           6             7           8           9 
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DNA in the lane in the nicked uncoiled form. Interestingly 10% of the DNA in the lane was of 
the linear form, showing that some double strand breaks occur. As this band only appears in 
the later lanes of prolonged illumination, it seems unlikely that the RuCy causes double strand 
breaks and the presence of the linear plasmid band is simply the result of two single strand 
breaks occurring together. This is expected as the RuCy is expected to form a y-shaped 
structure following a single strand break. During repeats, it was clear that a longer run time 
and stronger light could increase the degree of photocleavage, however, this was not desirable 
as more powerful bulbs create heat and longer exposure times become impractical, as 10 
hours is already an extensive amount of time. Instead, another experiment was done to look to 
increase the specificity of the energy absorbed to hopefully increase the degree of 
photocleavage. By looking at the absorption spectrum of the RuCy (Figure 4.9) the λmax 
occurs at 485 nm. By purchasing a 1W blue LED with a λmax emission at 474 nm, it was 
hoped that the degree of photocleavage would be enhanced without increasing the power 
output by simply concentrating the power into the wavelength range the RuCy absorbs. Figure 
4.10 shows example emission spectra of the two bulbs, illustrating the concentration of 
emission in the relevant region in the blue bulb compared to the white.  
Figure 4.10 - Emission spectra of a blue LED (left) and a white LED (right). 
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Figure 4.12 - Line graph illustrating the difference in photocleavage between wavelengths. 
 
With this in mind, the experiment was repeated with a 1W blue LED this time, the gel image 
obtained (Figure 4.11) shows that the earlier hypothesis was correct. The degree of DNA 
cleavage was significantly increased over the same time period with only 10% of the plasmid 
remaining undamaged. The amount of plasmid in the linear form also increased significantly 
showing move extensive double strand breaks; with the linear band starting to appear at 
around 4 hours into the experiment whereas the white light run only exhibited a small band 
around the 8 hour mark. The difference is illustrated clearly in the line graph in figure 4.12. 
 
 
 
 
 
 
 
 
 
 
   1             2           3           4            5           6           7           8           9 
Figure 4.11 - 1% Agarose gel run in 1 x TAE Buffer. Lanes 1 and 9 – control containing PuC19 
plasmid. Lane 2 – Plasmid under 24 hours of illumination. Lane 3 – Plasmid with RuCy (100 bp:1 
RuCy) with no illumination. Lanes 4-8 – Plasmid with Rucy with 2, 4, 6, 8 and 10 hours 1W blue light 
illumination respectively. 
 
Control lanes Increasing Irradiation 
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4.2.2 Photocleavage Mechanism 
Whilst a positive control experiment was firmly established, the energy mechanism of how 
the RuCy initiates photocleavage on the DNA was unclear. As discussed in the introduction, 
establishing the mechanism of photocleavage is important in the field of photodynamic 
therapy. Referring to the possible paths of photocleavage in the introduction to this chapter, it 
is possible to introduce inhibiting or enhancing substances to the reaction mixture, that if 
successfully alters the rate of photocleavage, should indicate the likely pathway. Some of 
these substances are well established in the literature for this purpose.22 One of these is 
sodium azide (10 mM in this experiment), an excellent quencher of 1O2 (singlet oxygen 
radicals).23 Another is to perform the experiment in D2O in place of H2O (50%). This is 
known to increase the lifetime of the 1O2 and thus if rate of cleavage is increased in the 
presence of D2O then this pathway is likely.
24 Finally, the presence of DMSO (10%), which is 
a hydroxyl radical scavenger,25 was assessed. 
The experiments were repeated as before, Figure 4.13 shows the effect of sodium azide and 
D2O on the reaction mixture in comparison to the control gel in Figure 4.11. It can be seen 
that sodium azide inhibits photocleavage by a small amount, suggesting that the mechanism 
proceeds through the 1O2 pathway. To back this up, the reaction performed in D2O also 
showed enhanced cleavage, showing the increased lifetime of the 1O2 is beneficial to the 
reaction. Other pathways such as through the production of a hydroxyl radial can also be ruled 
out as DMSO had no effect on the rate of cleavage compared to a tandem no DMSO sample. 
Through this information we can be confident that the mechanism proceeds through the 
singlet oxygen radical pathway which is in agreement with previous photocleavage studies on 
the RuCy.19  
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Figure 4.13 - Gel A – Control gel, Gel B – Sodium Azide treated samples, Gel C – D2O treated 
samples. Left hand graph) graphical quantification of gels A, B and C, performed at 100:1 
BP:RuCy Right hand graph) quantification of a separate experiment testing the effects of DMSO 
on cleavage. Performed at 200:1 BP:RuCy).  
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4.2.3 Photocleaving the DNA Tetrahedron 
Translating this working model onto the DNA tetrahedron required a different approach to 
visualise and quantify strand breaks in the experiment. This was because the nicked 
tetrahedron did not produce an obvious band shift like the plasmid in gel electrophoresis. In 
non-denaturing PAGE gels therefore, single strand breaks were found to produce bands that 
looked identical to intact tetrahedron. Two different experiments were carried out to try to 
observe the cleavage.  
The first involved forming a ‘ligated tetrahedron’, the formation of which was first outlined 
by Turberfield et al.26 This involves using a DNA ligase enzyme to close off nicks in the 
phosphosugar backbone on the edges of the DNA tetrahedron (Figure 4.14).  
 
By doing this after the tetrahedron has been formed, the strands become catenated together 
and when the DNA is denatured, four joint loops remain. This is advantageous as an 
undamaged ligated tetrahedron, when run on a denaturing gel, would produce a band 
containing all 4 undamaged strands. Any single strand breaks would release the damaged loop 
Figure 4.14 - Illustration of the formation of the ligated tetrahedron (Taken 
from 26) 
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from the catenated structure which would decrease the intensity of the undamaged band, 
allowing photocleavage to be observed. Figure 4.15 shows the resulting gel obtained. 
 
The first lane shows the unligated tetrahedron denaturing into 4 building block strands in the 
denaturing Urea conditions of the gel. Lane 2 shows successful ligation of the tetrahedron 
  1              2            3          4          5           6           7           8  
Figure 4.15 – Photo illumination image of a 10% Denaturing Page Gel. Lane 1: 
Non-Ligated tet. Lane 2: Lig Tet. Lane 3: Lig tet after 5 hours blue light irradiation. 
Lane 4-8: Lig tet with RuCy (2:1) irradiated with 0, 1,3,5 and 0 hours blue light 
respectively. 
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forming 4 single stranded DNA loops that cannot be separated by denaturation. Underneath 
the main band at the top, there are three fainter bands; these are products of incomplete 
ligation, corresponding to a 3 single stranded loop, 2 stranded loop, and 1 strand alone at the 
bottom, equal in migration to the deconstructed unligated tetrahedron in lane 1, confirming 
identity of the band. It is unclear as to why the ligation is not 100% effective. In previous 
similar experiments to this gel, ligation was left to proceed for 4 hours as per manufacture 
protocol and much less ligation efficiency was observed. Extended overnight ligation and 
excess T4 DNA ligase enzyme as shown here improved ligation efficiency to the point seen 
here, but total ligation was never achieved. This could be due to phosphorylation 
inefficiencies and due to the short sides of the tetrahedron not allowing enough space/DNA 
turns for the enzyme to initiate to full effect. Lanes 2 and 8 show that without RuCy, the blue 
light does not cause any damage to the DNA. As the duration of light irradiation increases, the 
tetrahedron is broken down until no intact DNA is left in lane 7. In lanes 5 and 6, it can be 
observed that bands attributed to the smaller structures increase in intensity. This gave some 
insight that the RuCy is cleaving initially at some point on one strand. Future work is 
currently planned to attempt to excise these photocleavage product bands and sequence them 
to try to see if the RuCy’s original binding and subsequent cleavage position on the 
tetrahedron can be found by analysing the starting sequences of the cleaved product and 
comparing them to the original construction strands. As irradiation continues, it is possible 
that the RuCy cleaves and can then re bind to resulting DNA and cause further cleavage; 
almost no observed DNA bands have been stained in lane 7, leaving only a smear low down 
the lane. Alternatively, the RuCy could remain bound inside a vertex and continues cleaving 
sequentially.  This suggests only very small randomly sized fragments remain as the SYBR 
gold stain could not be used to visualise them as they are so low in concentration. Overall, 
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this experiment was successful in proving that the DNA tetrahedron can be broken down with 
photocleavage from the ruthenium cylinder.  
The second visualisation method explored involved the ligated tetrahedron, but utilised 
another enzyme. Exonuclease III catalyses stepwise removal of nucleotides on a strand of 
DNA from the 3’ end, effectively digesting it.27 As the enzyme can only initiate on the end of 
DNA strands, if there are none, as with the ligated tetrahedron, no digestion should occur. If 
strand breaks are formed, however, the enzyme should be able to initiate and cause a decrease 
in the intact band intensity. In Figure 4.16 it can be seen that photocleavage has been a 
success. Initially, the construction of the tetrahedron can be easily tracked in lanes 1-4. Lane 5 
gave further evidence that ligation is not 100% efficient as the exonuclease was able to 
produce two digestion products, most likely the removal of 1 and 2 strands respectively 
leaving single stranded gaps in the tetrahedron structure. However, the migrations of these 
products do not match the ligated 2 and 3 stranded products presented in lanes 2 and 3. They 
are in fact slower. This could be due to incomplete removal of the strand, leaving the 
junctions intact. This would lead to a more rigid structure which would have decreased 
electrophoretic mobility and as such explain the slower migration.  On irradiation, the RuCy 
can be seen to produce many more strand breakages which lead to easier digestion by the 
enzyme. Again, after 5 hours irradiation in lane 9, no bands are visible, showing the enzyme 
has broken all the DNA down into single nucleotides and short, unstainable strands.  
Through both of these experiments, it is clear much less time is needed to photocleave the 
tetrahedron when compared to the plasmid DNA. One reason could be that the RuCy binds 
much more strongly to the tetrahedron than it does to plasmid DNA, facilitating quicker 
cleavage. This could be due to both the presence of 3WJs on the tetrahedron and the fact that 
plasmid DNA is supercoiled and could therefore be less accessible for the cylinder. 
157 
 
 
 
Figure 4.16 – Photo illumination picture 10% Non-denaturing PAGE gel. Lane 1: Strand 1 ligated, 
Lane 2: Strands 1 + 2 ligated, Lane 3: Strands 1 + 2 + 3 ligated, Lane 4: Full Ligated tetrahedron. 
Lane 5: Lig-tet exposed to Exonuclease III for 30 mins after no light irradiation. Lane 6: Lig-tet with 
2:1 RuCy and no light with Exonuclease III. Lanes 7-9, same as lane 6 but with 1, 3, 5 hours of 1W 
Blue LED illumination respectively. Lane 10: Control Lig-Tet only with 5 hours light and digestion. 
Gel stained with SYBR-Gold nucleic acid stain. 
   1      2        3       4       5       6        7      8       9        10  
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4.2.4 Initial Photodynamic Therapy Testing 
Ruthenium cylinder for this section was kindly provided by Dr Lucia Cardo 
With positive results obtained with the RuCy as a photocleavage agent, some initial in vitro 
testing was carried out to test whether the RuCy and RuCy-tetrahedron conjugate could enter 
cells, bind to cellular DNA and on excitation with blue light cause damage that triggers cell 
apoptosis. The focus now would be using the DNA tetrahedron as a delivery agent and 
targeting nuclear DNA for photocleavage. There are some key questions that it was hoped the 
testing would address. Firstly, confirmation was sought that extensive illumination with the 
blue light would not be harmful to cells alone. This would be desirable as current PDT 
therapies often use powerful lasers or strong fibre optic lights that produce excess heat and 
causes tissue damage in patients in the treatment area.13 From the start of this section it was 
the aim to be able to cause DNA damage with a bulb that does not cause excess heat or at a 
wavelength that damages DNA alone. 
A second aim was that without light excitation, the complexes would not be toxic to cells at 
doses shown to be active upon photo activation. This is important as low toxicity in vitro 
would suggest low side effects outside of the irradiated area and provide a large therapeutic 
window which would be advantageous relative to current cancer therapeutics.  
Finally, as ICP-MS results shown in chapter 3, it was hoped that the increased cellular 
accumulation of RuCy when delivered by the tetrahedron as opposed to cylinder alone would 
cause an enhanced effect of photo activated toxicity in cells. A decrease in activity is also 
possible as some of the RuCy may remain bound to the tetrahedron and instead cause strand 
breaks to it. This decrease in activity was observed in MTT assays shown in chapter 3 also 
when delivering FeCy with tetrahedron.  
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The initial experiment involved a crude set up using a desk lamp fitted with the same LED 
bulb used throughout the chapter. 96-well plates could then be fitted to the lamp at a measured 
distance. Only wells directly above the bulb were used in an attempt to make each well 
receive the same intensity of light. The set-up, however, will need to be optimised in future to 
guarantee this. Two 96-well plates were seeded with HeLa cells and following treatment with 
the complexes, one plate was irradiated with the lamp. The other dark control plate was also 
left out of the incubator and kept in darkness. It was kept outside of the incubator as it proved 
impossible to set up the lamp inside a temperature controlled incubator and so to ensure cell 
death contributed to by 2 hours of room temperature exposure, the control was kept in the 
same conditions.  
After irradiation, the cells were incubated for 24 hours to allow the apoptosis mechanisms to 
initiate in response to any possible DNA damage caused. Following this a standard MTT 
assay was performed to establish cell viability for each of the samples. Figure 4.17 shows the 
results of this experiment.  
From these results, it can be seen that the first aim of the experiment has been achieved to a 
large extent. The blue light has only a small effect on the cell viability (~15%) in comparison 
to the dark control in the absence of any complexes. The data is noisy but it is worth noting 
that these are still preliminary experiments and more repeats of this experiment will need to 
be performed before it is statistically significant.  
The second aim of the experiment was to show the complexes are non-toxic to a large extent 
without light irradiation. Here it can be seen that the RuCy reduces cell viability to 50% by 10 
µM treatment. This was surprising as previous unpublished work within the Hannon group on 
RuCy show the toxicity to be lower than seen here. However, at concentrations of 1 and 2 
160 
 
µM, the cell viability is much more acceptable at 85% and 75% respectively. The RuCy-
tetrahedron conjugate exhibited similar behaviour to the MTT assays in chapter 3 in that the 
cylinder toxicity was reduced. This result could suggest the tetrahedron could have 
applications guarding against cell toxicity when it is not desired such as in this case.  
 
When observing the cell viability after light irradiation, the RuCy exhibited very high activity. 
At 2 µM almost no cells were viable, which is significantly different from the dark treatment 
at the same concentration. The RuCy-tetrahedron conjugate, however, exhibited disappointing 
toxicity on light irradiation. At 2 µM cell viability is at 55% which is more toxic than the dark 
control, but considerably less than free cylinder. The toxicity does not change much at all with 
increase in concentration to 10 µM. This could be because at 2 µM and above, the cylinder 
and the tetrahedron don’t readily dissociate and instead the irradiation simply photo cleaves 
the tetrahedron instead of cellular DNA. This effect could be advantageous as cleavage could 
be limited to the tetrahedron to release an internal cargo without causing a toxic effect. 
Alternatively, addition irradiation time could cleave the tetrahedron, releasing RuCy to then 
bind cellular DNA and perform secondary cleavage. As observed before, the tetrahedron 
alone does not have any toxicity and on irradiation, this also remains the case.  
Whilst these experiments need more repeats, future experiments could optimise the treatment. 
Decreasing the treatment time before irradiation from 24 hours could reduce toxicity from the 
complexes in the dark control. It may also be possible to reduce the irradiation time to make 
the treatment more practical as the RuCy could have potent activity at far less irradiation time 
than 2 hours.  
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Figure 4.17 – MTT assays of HeLa cells (Cervical) N=1 with data points performed 
in duplicate. Top) Cell viability when cells have been treated and kept in the dark. 
Bottom) Cell viability after 2 hour irradiation with blue light. Absorbance has been 
normalised to the dark 0 µM data to offer easy comparison. 
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4.3 Conclusions 
Overall, the RuCy was shown to be able to bind to DNA and act as a photosensitizer leading 
to DNA damage. This was shown to be possible even using a weak light source. This opens 
up further possible research into the area of photodynamic therapy.  
When bound to the DNA tetrahedron, the RuCy was shown to break down the structure in 
two different experiments. This was especially interesting as it is the first time to our 
knowledge that a photosensitizer has been used in the fashion. In terms of future research, it 
could be possible to encapsulate a cargo that would be then released following light 
irradiation. As the tetrahedron-cylinder conjugate has already been shown to enter cells, 
internal cargo such as cytotoxic viruses28 or peptides, the latter of which often are degraded 
by proteolysis  before it makes it to cells29, could be carried into cells in the body and then 
activated in that area using light.  
In initial PDT testing in vitro, the RuCy was shown to have extremely potent cytotoxic 
activity on irradiation with blue light. (More repeats needed but impossible at the time due to 
lack of RuCy due to the problematic synthesis). The effect is diminished with the RuCy-
tetrahedron conjugate, but this could provide an opportunity to use the conjugate to deliver a 
different internalised cargo. It is also worth noting that translating these positive results to an 
in vivo model could be problematic, this is because light in the red region of the spectrum has 
the best tissue penetration, able to activate effectively around 3 mm deep. Blue light however, 
can only activate compounds to a depth of 1 mm.30 Medical devices and light sources for this 
exact purpose however, are being improved at rapid pace which could minimise this decrease 
in efficiency.  
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4.4 Experimental 
Materials: Plasmid DNA and enzymes T4 polynucleotide Ligase, T4 polynucleotide Kinase 
and Exonuclease III were purchased from New England Biolabs. All chemicals were 
purchased from Sigma Aldrich unless otherwise stated. DNA oligonucleotides were 
purchased from Eurofins reverse phase HPLC purified. Pre-mixed Acrylamide / 
Bisacrylamide Stabilized Solution for gel electrophoresis was purchased from National 
Diagnostics. ATP-32 was sourced from Perkin Elmer. Molecular grade agarose powder was 
sourced from Bioline. SyBr Gold nucleic acid stain was purchased from Life Technologies. 
The blue and white LED bulbs used for photoactivation was purchased from electrical world 
with a GU10 fitting.  
  
Synthesis of Parent Ligand (L: C25H20N4) 
4,4’Methylenedianiline (1.99g, 0.01 mol) was dissolved in ethanol (10 ml). To this solution, 
pyridine-2-carboaldehyde (1.90 ml, 0.02 mol) was added. The solution was then left to stir 
overnight. The yellow precipitate formed was then collected by vacuum filtration. The crude 
product was then purified by re-crystallisation from ethanol (3.50 g, 93% yield). The product 
is a pale yellow solid.  
 
Mass Spectrum (ESI): m/z = 399 {M+Na} 
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1H NMR (300 MHz), CDCl3, 298K): δ 8.71 (2H, d, J = 3.9 Hz, 6py), δ 8.63 (2H, s, J = Him), δ 
8.22 (2H, d, J = 7.0 Hz 3py), δ 7.82 (2H, td, J = 8.3, 1.9, 0.6 Hz, 4py), δ 7.40 (2H, ddd, J = 
7.6, 4.9, 1.2 Hz, 5py), δ 7.30 (8H, m, Pha and Phb), δ 4.08 (2H, s, CH2) 
 
Synthesis of Ruthenium Cylinder, [Ru2(L)3](PF6)4: RuCl3 (3g, 14.5 mmol) was dissolved 
in 15 mL of DMSO and heated under reflux at 195oC for 5 minutes. The solution was reduced 
in vacuo to concentrate the solution down to 1 mL. Excess cold acetone was then added to 
precipitate a yellow solid. The yellow precipitate was then filtered and washed with cold 
acetone to furnish the yellow solid Ru(DMSO)4Cl2.  
Ru(DMSO)4Cl2 (0.988 g, 2.04 mmol) and parent ligand (1.150 g, 3.06 mmol) were added to 
degassed Ethylene glycol (50 ml) and heated to reflux under argon at 200oC for 5 days. The 
mixture was allowed to cool and an excess saturated methanolic solution of ammonium 
hexaflourophosphate was added. The suspension was cooled on ice before the precipitate was 
filtered and washed with methanol (2 x 40 ml) and dried with ether (3 x 100 ml). The dark 
brown product was purified by column chromatography on alumina using 20:1:1 MeCN/H2O/ 
KNO3(aq) solution as eluent to yield the product as an orange solid (11 mg, 0.6% yield). The 
chloride complex could be formed by anion metathesis.  
Mass Spectrum Positive ion ESI: m/z = 666 [M-(PF6)4]
2+, 444 [M-(PF6)]
3+ , 333.2 [M-(PF6)
4+ 
1H NMR (300MHz), CD3CN, 298K : δ = 8.7 (2H, s, Him), 8.45 (2H, d, J = 7.6 Hz, 6py), 8.35 
(2H, td, J = 7.78 Hz, 5.0 Hz, 3py), 7.65 (2H, d, J = 6.0 Hz, 4py), 7.65 (2H, d, J = 6.0 Hz, 5py), 
7.0 (4H, d, J = 8.4 Hz, Pha/b), 5.7 (4H, d, J = 8.3 Hz, Pha/b), 4.1 (2H, s, CH2) 
UV-Vis (CH3CN) : λmax   (ε / dm3 mol-1 cm-1)  485 (24200)  
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Plasmid Photocleavage: PuC19 plasmid (200 ng per sample) in Tris.HCl buffer (50mM pH 
8.0) was incubated with RuCy (0.33 µM) to a final volume of 10 µL for 1 hour in the dark in 
0.5 mL Eppendorfs. Samples were then illuminated for the allotted time over either a 1W blue 
or 1W white LED bulb. Samples not requiring illumination were then kept at 4oC in the dark.   
Agarose Gel Electrophoresis: 1% agarose gel was prepared by mixing 0.9 g agarose in 1 X 
TAE buffer (40mM Tris, 20mM Acetic Acid, 1mM EDTA, pH 8.5) and heated in a 
microwave until fully dissolved. The gel was allowed to cool to around 60oC before being 
poured into a 20x15 cm gel cassette in a casting tray, ensuring any bubbles created were 
removed with a spatula. The gel was allowed to cool and set fully for 60 mins. Once set the 
gel was placed inside the buffer tank and immersed in 1 x TAE buffer. Samples were then 
loaded into the wells, using purple gel loading dye (New England Biolabs) to aid in 
visualisation and to help the samples settle in the well. The gel was then run at 4V/cm for 120 
mins. The gel cassette was then removed from the tank and stained using SYBR gold nuclear 
acid gel stain (Invitrogen) for 30 mins. The gel was then photographed and analysed using a 
UV transilluminator (AlphaImager HP, ProteinSimple). 
Ligated Tetrahedron Construction: Four oligonucleotides were purchased from Eurofins, 
each of 63 bases in length. The sequences were as follows: 
1: AGGCAGTTGAGACGAACATTCCTAAGTCTGAAATTTATCACCCGCCATAGTAGACGTATCACC 
2: CTTGCTACACGATTCAGACTTAGGAATGTTCGACATGCGAGGGTCCAATACCGACGATTACAG 
3: GGTGATAAAACGTGTAGCAAGCTGTAATCGACGGGAAGAGCATGCCCATCCACTACTATGGCG 
4: CCTCGCATGACTCAACTGCCTGGTGATACGAGGATGGGCATGCTCTTCCCGACGGTATTGGAC 
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All strands were reverse-phase HPLC purified. Each strand was then phosphorylated by 
mixing 2.4 µl of 100 µM of the oligonucleotide with 9.6 µl of MilliQ water, 2 µl of 10 x T4 
polynucleotide kinase buffer, 2 µl of bacteriophage T4 polynucleotide kinase and 4 µl of ATP 
in an Eppendorf and leaving to incubate at 37oC for an hour before heat inactivation at 80oC. 
Each phosphorylated strand was then purified using a QIAquick nucleotide removal kit 
following a previously discussed protocol in chapter 2.  Stoichiometric quantities of each 
phosphorylated strand were mixed in TM buffer (10mM Tris base, 5mM MgCl2, pH 8) and 
heated to 95 oC in a thermal block for 5 minutes. On cooling at room temperature for 30 
seconds, the eppendorf was placed on ice for 5 minutes and then centrifuged for 5 seconds. 
10mM DTT and 1 µL per 10 µL of reaction mixture of T4 DNA ligase enzyme was added and 
the resulting mixture left to incubate for 24 hours at room temperature. The enzyme was once 
again heat inactivated at 70oC for 10 mins and the resulting DNA product purified on a 10% 
denaturing PAGE gel and the excised DNA concentration check by UV-Vis.   
 
Ligated Tetrahedron Photocleavage: 5 µL of LigTet was mixed with 0.75 mL of 10 µM 
RuCy and 4.25 µL of MilliQ H2O. The sample was then irradiated under 1W Blue LED light 
for the allotted time before being stored at 4oC in the dark. 
 
DNA digestion: Samples to be digested were first bufferd to 1x concentration using 10x 
NEBuffer 1 (New England Biolabs). 1 µL of Exonuclease III (New England Biolabs) per 10 
µL of reaction mixture was then added. The mixture was incubated for 30 mins and heat 
inactivated at 70oC for 10 mins.   
Denaturing Gel Electrophoresis: 10% denaturing polyacrylamide gel was prepared by 
mixing 17 mL 30% 29:1 acrylamide/bis-acrylamide, 5 mL 10x TB buffer, 24g Urea, 25 µL 
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TEMED, 230 µL 10% ammonium persulfate solution and topped up to 50 mL with dd H2O 
and leaving to set between two glass plates with a comb for 60 mins. The samples where then 
loaded and run at 11V /cm of gel for 180 mins. The gel was then removed from the plates and 
stained with SYBR gold nucleic acid get stain for 30 mins before being visualised and 
photographed under a UV transilluminator.   
Native Polyacrylamide Gel Electrophoresis: 10% Native gel was prepared by mixing 17 
mL 30% 29:1 acrylamide/bis-acrylamide, 5 mL 10x TB buffer, 25 µL TEMED, 230 µL 10% 
ammonium persulfate solution and topped up to 50 mL with dd H2O and leaving to set 
between two glass plates with a comb for 60 mins. The samples were then loaded and run at 
11V /cm of gel for 180 mins. The gel was then removed from the plates and stained with 
SYBR gold nucleic acid get stain for 30 mins before being visualised and photographed under 
a UV transilluminator.   
Photodynamic Therapy MTT  
HeLa cells were seeded into two 96-well plates at 5000 cells per well, each well containing 
200 µL of DMEM. This plates were left for 24 hours before being treated with the complexes 
to the final concentrations indicated to a volume of 100 µL in DMEM. Cells were incubated 
for a further 24 hours with the complexes. One plate was then irradiated with a 574 nm blue 
LED bulb for 1 hour before being placed back inside the incubator for 15 minutes to retain a 
temperature of 37oC before another hour of irradiation. Following this, cells were then 
incubated for a further 24 hours before cell viability was checked through a standard MTT 
assay described above. 
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Chapter 5  
 
 Targeting the trans-activating response element (TAR) in 
the HIV Virus to prevent replication 
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5.1 Introduction 
The human immunodeficiency virus (HIV) is a lentivirus which is a part of a larger group of 
viruses known as retroviruses.1 The virus once inside human cells causes acquired 
immunodeficiency syndrome which is characterised as a total failure of the human immune 
system. Without an immune system, patients become very vulnerable to many illnesses and 
diseases which invariably are fatal. Without treatment, a person infected with HIV can expect 
to live around 9-11 years.2 HIV is spread through sharing of many types of bodily fluids, 
mainly blood and genital fluids and it is estimated, as of 2015, 36.7 million people were 
infected with HIV and in the same year 1.1 million people died due to illnesses and diseases 
caused by AIDs.3 Whilst many drugs have been developed over recent years that have been 
able to manage the disease, a cure still remains elusive.  
The HIV viron itself is a spherical structure of about 120 nm in diameter and Figure 5.1 
shows a basic overall structure.4 The main features include the 2 single strands of RNA which 
Figure 5.1 - Schematic diagram of the HIV virus. Taken from 4.  
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hold the sequences of the 9 genes of HIV needed to replicate inside the host cell. These are 
joined inside the central capsid by the enzymes key to the replication cycle: protease, 
integrase, ribonuclease and reverse transcriptase.5 This internal capsid is all enclosed by the 
viral protein for integrity. Around this capsid is a viral envelope, comprised of a lipid bilayer, 
which on the surface contains two key proteins, glycoprotein (gp) 120  and gp 41.6 These two 
proteins are key to enabling the virus to attach and merge into host cells.  
The lifecycle of the virus has been important to drug development as targeting different stages 
of the cycle has led to key breakthroughs in the field. Figure 5.2 illustrates the major steps of 
the cycle of HIV.7 It begins with the glycoproteins on the virus binding to CD4 receptors on 
the membrane of a host cell. These types of cells tend to be macrophages and T cells. Once 
bound, the virus can then fuse with the host cell and release the internal RNA and enzymes 
Figure 5.2 - The life cycle of the HIV virus. Taken from 7. 
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into the cell. The ssRNA then undergoes reverse transcription to form dsDNA which is then 
localised to the cell nucleus. The enzyme integrase can then integrate this viral DNA into the 
host cell genome. This DNA codes for the cell to produce new ssRNA and mRNA, which 
produces key viral proteins, all to form new virons. These ‘bud’ together at the host cell 
membrane to form new virus capsules which then exit the cell.8  
This step-wise cycle provides very clear targets for drug design and has led to five major anti-
viral drug families. Entry inhibitors target the binding between the CD4 receptors on the host 
A B 
C 
Figure 5.3 – A) Structure of Maraviroc, B) structure of Zidovudine, C) structure of 
Saquinavir. Taken from refs 9, 12 and 19 respectively. 
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cell and the GP120 on the viron in the very first stage of the cycle. Maraviroc (figure 5.3a) is 
one such inhibitor.9 Fusion inhibitors work in a similar fashion, but target the GP41 on the 
virus membrane which is responsible for fusing the virus with the host cell membrane. 
Enfuritide is a licensed drug that does exactly this, by binding to GP41, it prevents entry to 
host cells.10  
Reverse transcriptase inihibitors (RTIs) work by preventing the transcription of the HIV 
ssRNA to dsDNA, they do this by acting as a DNA base, but lacking a phosphate group 
which renders the transcriptase unable to continue once it has paired an RTI into the duplex.11 
The class contains the most available drugs and the first ever licensed HIV drug, Zidovudine 
(figure 5.3b).12 Integrase inhibitors work by preventing the transfer and integration of the 
dsDNA into the host cell nuclear DNA. There are many possible ways in which this can 
happen, but the main focus of research and development has been to prevent the initial 
binding of the viral DNA to the integrase enzyme before the transfer to the cell nucleus.13 
This is done by exploiting two features on the enzyme, a small hydrophobic pocket and two 
divalent Mg2+ sitting inside the enzymes active site.14 Successful drugs such as Raltigravir and 
Elvitegravir (Figure 5.4) show the consensus functional groups necessary for strong enzyme 
binding and potent integrase inhibition. A hydrophobic flouro-benzyl moiety, for the 
Figure 5.4 - Integrase inhibitors Elvitegravir (left) and Raltegravir (right)  
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hydrophobic pocket, and the hydroxyl-benzyl group flanked by 2 carbonyl groups to form a 
suitable chelation point for the two Mg2+ ions. 15,16 This actively outcompetes in binding with 
the HIV DNA and stops the cycle.  
The final class of drugs are known as protease inhibitors. These work by targeting the enzyme 
HIV1-protease, which works on newly released HIV virons. When initially released, the virus 
contains large proteins which must be broken down to form key structural parts of the virus 
and the internal enzymes. During this stage the virus is considered ‘immature’ and cannot 
infect new host cells.17 HIV1-protease breaks down these large proteins to mature the cell into 
the infective form. Peptide-like drugs have been developed which can bind to this protease, 
but contain an un-cleavable hydroxyethylen group which blocks enzyme action.18 The first 
drug of its class, Saquinavir (figure 5.3c) illustrates this functionality.19  
These five families of drugs have led to very effective multi-drug therapies which can keep 
levels of HIV virus in the body at very low, sometimes undetectable levels.20 Unfortunately, 
this drug regime does not fully eliminate the HIV virus from the body and if medication is 
ceased, a rapid increase of virus levels is observed.20 Whilst there is strong debate over the 
possible reservoirs harbouring virus, one theory for the survivability in the body is the role of 
the trans-activating regulatory (tat) protein. Tat protein is a small protein between 86 and 101 
amino acids long which regulates the transcription of the integrated HIV DNA by polymerase 
to produce full length HIV RNA transcripts.21 It does that by binding to a short looped piece 
of HIV RNA in a region called the trans-activator region (TAR).21 TAR and Tat bring 
together the positive transcription elongation complex (P-TEFb) and cyclin T1, Which 
facilitate the production of full-length viral RNA22(Figure 5.5).23 In the absence of Tat, non-
complete strands of HIV  RNA are produced which code for mRNA to produce tat protein to 
begin the cycle instead of full virons.24 This self-sustaining process leads to exponential 
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increase or ‘explosive’ increase in virus levels.24 Tat is released into the bloodstream to 
encourage further replication and also has apoptotic action against T-cells, protecting infected 
host cells from immune response.25 It is theorised that under current anti-retroviral regimes, 
tat protein is still secreted into the blood stream.26 This greatly assists the dormant, low 
population HIV reservoirs to repopulate rapidly if anti-retro viral therapy is ceased.27 Clearly 
this is an attractive target for a new family of anti-viral drugs. 
 
In 1993 Churcher et al. identified and characterised the TAR-TAT interaction in vitro by gel 
electrophoresis using synthetic RNA to mimic the looped region (Figure 5.6).28 Since then 
there have been some attempts to target this interaction, such as with peptides that 
Figure 5.5 - A schematic diagram illustrating the binding location of TAR RNA and 
Tat protein on RNA polymerase and the products of binding. Taken from 21. 
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competitively bind the TAR RNA.29 However, no attempts have yet made it to the clinic. 
Previous studies in our group on cylinders have shown the ability of the iron cylinder to bind 
to DNA bulged regions.30 Following on from this, it was shown that the iron cylinder could 
bind to the 3-base bulge on TAR RNA.31 This chapter aims to assess the binding capabilities 
of both the ruthenium cylinder and a nickel cylinder to TAR RNA, the potential inhibition of 
tat binding and subsequent anti-viral activity.  
 
5.2 Results and Discussion 
5.2.1 Gel Electrophoresis 
Nickel and ruthenium cylinders for this section were kindly provided by Dr Lucia Cardo. 
After observing the potent anti-viral activity possessed by the cylinders. It is important to 
verify whether the activity is due to the inhibition of Tat protein binding to the TAR RNA 
looped region. To do this, a 31-mer RNA strand was synthesised (Integrated DNA 
Figure 5.6 - Structure of the looped region of TAR RNA, showing the 3 base UCU 
bulge where both cylinder and Tat protein bind. Taken from 31. 
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Technologies) (Figure 5.6). Samples of the RNA were then incubated with each of the 
cylinders and run on a non-denaturing gel. Figure 5.7 shows the gels obtained. With 
increasing concentration of each of the cylinders, the RNA band migration is slowed. This is 
indicative that all the cylinders, iron, nickel and ruthenium all have an affinity for the RNA 
loop. This is due to the bulky nature of the cylinders creating a larger overall complex which 
migrates more slowly through the gel. The positive charge on the cylinders also negates some 
of the negative charge on the RNA, which in turn means the cathode has less of a negative 
charge to attract through the gel. It is difficult to see here if any of the cylinders have more of 
an effect each other and any differences would be subtle anyway, but it is certain that they all 
bind. 
 By designing the synthetic RNA to be as short as possible, cylinder binding to duplex DNA 
was unlikely in the tail regions, making bulge binding the most probable mode. Although 
efforts continue to obtain a crystal structure of this, it remains elusive to fully confirm the 
cylinder binding position. At this point however, it is the most likely binding position.  
- - + - + + 
    1         2       3      4       5       6       7      8        9     10     11     12   13     14     15 
[Fe2L3]Cl4 
Figure 5.7 – Autoradiogram showing the effect of the cylinders on the TAR RNA (2 µM). 
Control wells 1, 6 and 10 containing RNA only. Wells 2-5 containing increasing concentrations 
of iron cylinder (1, 2, 3 and 4 µM respectively); Wells 7-10 containing increasing 
concentrations of nickel cylinder (1, 2, 3 and 4 µM respectively) and wells 12-15 containing 
increasing concentrations of ruthenium cylinder (1, 2, 3 and 4 µM respectively). 
-ve 
+ve 
[Ru2L3]Cl4 [Ni2L3]Cl4 
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5.2.2 ADP-1 Binding 
The next step in the investigation was to observe binding between the TAR RNA and Tat 
protein. However, by utilising a short fragment of TAR, binding to the full HIV-1 tat protein 
proved very difficult to replicate in-vitro with this particular sequence. Instead, Churcher et 
al. had reported the main regions of the 101-amino acid recombinant tat protein for binding to 
TAR.28 By synthesising the polypeptide ADP-1, containing amino acid residues 37-72 with a 
sequence of SFTTKALGISYGRKKRRQRRRPPQGSQTHQVSLSKQ with serine replacing 
cysteine in position one to reduce oxidation probability31 it was possible to create an in-vitro 
model of the binding interaction. Figure 5.8 illustrates by form of gel electrophoresis the 
complex band formed when ADP-1 peptide is added in increasing concentrations to a 
radiolabelled sample of TAR RNA. 
 
TAR RNA 
TAR-ADP Complex 
-ve 
+ve 
- + ADP peptide concentration 
Figure 5.8 – Autoradiogram illustrating the complex formed between TAR RNA (0.1 µM) 
and the ADP-1 peptide. With increasing peptide concentration (0.2 – 1.0 µM) the band 
intensity corresponding to complex increases. 
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5.2.3 Inhibition of binding using a range of Cylinders 
With a positive control established, the extent of the ability of the cylinders to inhibit RNA-
peptide binding could be assessed. This would also confirm that anti-viral activity observed is 
in fact partly due to this action. Figure 5.9 shows representative polyacrylamide gels of three 
identical repeat experiments involving the iron, nickel and ruthenium cylinders. Each gel 
shows the band corresponding to RNA-peptide binding as before. With increasing cylinder 
concentration, the intensity of this band diminishes. This is due to cylinder competitively 
binding with the RNA bulge, blocking binding action of the peptide. All three cylinders 
clearly exhibit this action. Another feature of the gels on figure 5.9 is the retardation of the 
RNA band upon cylinder binding that is also observed in figure 5.7. This further confirms 
cylinder competitively binding RNA and blocking peptide binding.  
By quantifying the RNA-peptide band, an attempt can be made to compare the inhibition 
action of each of the cylinders. Figure 5.10 shows raw data of the percentage of RNA-peptide 
complex against concentration of cylinder (average data of 3 repeat experiments for each 
cylinder). The nickel cylinder immediately appears to be most active in blocking complex 
formation. 
The iron and ruthenium both have similar activity within the error bars on the graph, but the 
nickel cylinder has consistently the most potent action, followed by the iron cylinder and then 
the ruthenium. This cause of this trend is hard to confirm. With regards to aqueous stability, 
the ruthenium cylinder is the most stable, followed by the NiCy with the FeCy the least stable. 
In vitro cell toxicity trends to run the opposite way, showing the FeCy the most active and 
RuCy the least. The crystal structures of the cylinders show the size and shape of all three are 
very comparable, it is possible however, that subtle changes in ligand orientation amongst the 
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Figure 5.9 - Autoradiograms illustrating the inhibition of the formation of the ADP 
peptide (300 nM) – TAR RNA (100 nM) complex, with increasing cylinder concentration 
(0.2 µM – 1.6 µM), less complex is able to form due to cylinder binding to RNA. 
Retardation of RNA band is observed confirming cylinder binding. Each gel image is one 
representative of three identical repeat PAGE experiments. 
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metals could be responsible for the difference in the binding strength to this specific RNA 
loop. Further experimentation is needed to fully confirm this trend such as NMR or X-ray 
crystallography of the cylinders-RNA complex.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 – Line graph illustrating the inhibition of RNA (100 nM) – ADP-1 (300 nM)  
binding through addition of increasing concentrations of cylinder from 0-1.6 µM. Error bars show 
the standard error of the mean where n=3. 
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5.3 Conclusions 
From these experiments, iron, nickel and ruthenium cylinders were shown to be able to inhibit 
TAR-ADP-1 complex formation by binding to the TAR RNA looped region. Follow on 
experiments in collaboration with Dr Lucia Cardo and Dr Isabel Nawroth have shown that the 
cylinders can inhibit HIV replication in cellulo in mammalian HIV infected cell lines, With 
the RuCy proving particularly effective. To further prove the effectiveness of these cylinders, 
the cytotoxicity of each of the cylinders was tested against the same cell lines, showing the 
nickel cylinder to have minimal cytotoxicity during anti-viral treatment whilst the ruthenium 
had a modest cytotoxic effect. The iron cylinder, however, proved to be too cytotoxic to be 
considered useful as an anti-viral agent.  
This new class of anti-viral agents is particularly interesting as many viruses can mutate viral 
sequences and vary RNA bulge shapes to develop sequence specific drug resistance.32 
However, the TAR RNA bulge appears to be essential to TAT recognition and therefore HIV 
replication. This means the only mutations the virus has been observed exhibiting here have 
been sequence changes within the bulge sequence rather that structural. As the cylinder binds 
the bulge structure and not the sequence, the cylinder would not be affected by such viral 
mutations. The cylinder has also been shown to be able to bind to a wide variety of bulge 
structures, not just this one,30 which provides further advantage against any possible viral 
structural mutations.  
Therefore, these experiments have shown that targeting RNA structures which are prevalent 
in a wide variety of viruses33 is an effective new approach to anti-viral research.  
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5.4 Experimental 
Ruthenium and nickel cylinders were provided by Dr Lucia Cardo and were synthesised by 
following previously reported synthesis.34, 35 The synthetic oligoribonucleotide (TAR) (Figure 
5.6) was purchased from Integrated DNA technologies ready reverse phase HPLC purified. 
ADP peptide was purchased from Schafer-N (Copenhagen, Denmark). Pre-mixed 
Acrylamide / Bisacrylamide Stabilized Solution for gel electrophoresis was purchased from 
National Diagnostics. ATP-32 was sourced from Perkin Elmer. T4 Polynucleotide kinase was 
purchased from New England Biolabs. 
 
Synthesis of Parent Ligand (L: C25H20N4) 
4,4’Methylenedianiline (1.99g, 0.01 mol) was dissolved in ethanol (10 ml). To this solution, 
pyridine-2-carboaldehyde (1.90 ml, 0.02 mol) was added. The solution was then left to stir 
overnight. The yellow precipitate formed was then collected by vacuum filtration. The crude 
product was then purified by re-crystallisation from ethanol (3.50 g, 93% yield). The product 
is a pale yellow solid.  
 
Mass Spectrum (ESI): m/z = 399 [M+Na] 
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1H NMR (300 MHz), CDCl3, 298K): δ 8.71 (2H, d, J = 3.9 Hz, 6py), δ 8.63 (2H, s, J = Him), δ 
8.22 (2H, d, J = 7.0 Hz 3py), δ 7.82 (2H, td, J = 8.3, 1.9, 0.6 Hz, 4py), δ 7.40 (2H, ddd, J = 
7.6, 4.9, 1.2 Hz, 5py), δ 7.30 (8H, m, Pha and Phb), δ 4.08 (2H, s, CH2) 
 
Synthesis of the triple stranded iron helicate [Fe2(L)3]Cl4 
Ligand (3.0g, 0.008 mol) was dissolved in methanol (400 ml). Iron (II) chloride tetrahydrate 
(1.06 g, 0.005 mol) was then added to the solution and the resulting solution was brought to 
reflux at 65oC for 3 hours. The solution was then taken to dryness in vacuo. The crude 
product was then dissolved in minimal amounts of methanol (10 ml) and excess methanolic 
ammonium hexafluorophosphate added. The resulting precipitate was collected by filtration 
and washed with water (2 x 10 ml) and then diethyl ether (5 x 25 ml). The filtrate was then 
suspended in methanol and stirred with Dowex until the product had dissolved. The Dowex 
was then filtered off. The filtrate was taken to dryness in vacuo, and then redissolved in a 
minimum amount of methanol. Excess diethyl ether was added until the product precipitates, 
the final product was filtered and washed with ether and dried (1.65g, 59.7%). The final 
product was a crystalline purple solid.   
 
Mass Spectrum (ESI): m/z = 425.5 [Fe2L3]Cl
3+ , 310 [Fe2L3]
4+ 
1H NMR (300 MHz), CD3OD, 298K): δ 9.13 (2H, s, Him), δ 8.71 (2H, d, J = 7.2 Hz, 6py), δ 
8.48 (2H, t, J = 7.8, 3py), δ 7.84 (2H, ddd, J = 5.6, 4py), δ 7.44 (2H, d, J = 5.2, 5py), δ 7.05 
(4H, broadened,  Pha/b), δ 5.62 (4H, broadened, Pha/b), δ 4.07 (2H, s, CH2) 
UV-Vis (H2O), λmax (ϵmax/dm3mol-1cm-1) 584 (16900) nm   
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Cylinder - TAR RNA binding – A synthetic 31 base RNA strand of sequence 5’ 
GGCCAGAUCUGAGCCUGGGAGCUCUCUGGCC 3’ was purchased from Integrated 
DNA Technologies (IDT) HPLC purified. RNA was radiolabelled at the 5’ end using T4 
polynucleotide kinase and [γ-32P]ATP. RNA was then annealed in 50 mM Tris HCl (pH 8.0) 
at 80oC for 5 min and then 10 min at 4oC on ice. RNA samples (2 µM) were incubated with 
increasing cylinder concentrations (1-4 µM, relating to ratios of 0.5, 1, 1.5 and 2 cylinders per 
RNA strand) of cylinder in TK buffer; Tris HCl (50 mM, pH 8.0), KCl (100 mM) to a final 
volume of 10 µL for 30 min at RT and then on ice for 10 min. Samples were then run on a 
15% non-denaturing polyacrylamide gel in 0.5 x TB buffer; Tris.HCl (40mM), Boric acid (45 
mM), pH 8.3 at 11 v/cm and 4oC for 5 hours. Gel was imaged by developing on a white 
phosphor screen and scanned using a Bio-Rad personal molecular imager (PMI). 
ADP-RNA binding inhibition – The TAR RNA was radiolabelled and annealed as before. 
10 µL sample solutions containing final concentrations of TAR RNA (100 nM) DTT (100 
mM) ADP peptide (300 nM), 0.1% Triton X-100, Tris.HCl (50 mM pH 8.0) and cylinder (Fe, 
Ni or Ru at 0.2, 0.4, 0.8 and 1.6 µM, corresponding to ratios of 2, 4, 8 and 16 cylinders per 
RNA strand)  were prepared and incubated at RT for 30 min and then on ice for 10 min. 
Samples were run on a 10% non-denaturing polyacrylamide gel at 4oC for 2.5 hours at 
11v/cm. Gel was imaged by developing on a white phosphor screen and scanned using a Bio-
Rad personal molecular imager (PMI). 
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Chapter 6 
 
Conclusions and Future work  
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6.1 Conclusions and Future Work 
6.1.1 Conclusions 
Overall, this thesis has shown that the iron cylinder and its enantiomers can bind to a DNA 
tetrahedron and, upon binding, cause the structure to contract, potentially having the effect of 
decreasing the size of the internal cavity. It was also found that increasing the ratio of cylinder 
to DNA tetrahedron increases the compression effect on the tetrahedron. However, at high 
ratios, the positive charge of the cylinder overcomes the negative charge on the DNA and causes 
the conjugate to precipitate out of solution. Whilst it proved very difficult to ascertain where 
exactly the cylinder was bound to the tetrahedron, separate gel electrophoresis competition 
experiments showed the cylinder has a much higher affinity to 3WJ structures over duplex 
DNA, suggesting the cylinder preferentially binds to the 3WJs on the tetrahedron over the 
duplex DNA present. Interestingly when the M and P enantiomers were separated and then 
combined with the tetrahedron, the M enantiomer had a stronger effect than the P enantiomer 
compressing the tetrahedron. This was interesting as previous experiments showed only the M 
enantiomer bound inside 3WJs in crystallographic experiments using racemic cylinder, 
suggesting that the M enantiomer prefers to bind to the 3WJ DNA in the tetrahedron more so 
than the P enantiomer.  
This opens up further research into other DNA nanostructures that cylinders could bind to and 
effect. Potentially creating DNA nano-machines in conjunction with supramolecular chemistry. 
The cylinder-tetrahedron conjugate was also found to be readily taken up by mammalian cells 
through a variety of experiments. The cytotoxicity of the cylinder, when delivered by 
tetrahedron was diminished but still remained potent. This was most likely due to an 
equilibrium of binding for the cylinder between genomic DNA and tetrahedron DNA, reducing 
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the amount of cylinder available to cause apoptosis through genomic DNA binding. Initial 
results using an almost identical ruthenium cylinder with ICP-MS suggested that overall uptake 
of cylinder is increased when delivered by tetrahedron, in the cytoplasm and nucleus. Whilst 
considerable research has already been published on the merits of DNA nanotechnology as 
therapeutic carriers; this particular research shows supramolecular chemistry can also play a 
role in the field.   
The ruthenium cylinder has DNA photocleavage capabilities that are most effective in the blue 
end of the spectrum, centred on its absorption maxima at 474 nm. This was very interesting 
when combined with the DNA tetrahedron as it was shown that the tetrahedron could be broken 
down on excitation with a specific wavelength of light, suggesting that potential internalised 
cargos could be released on excitation with the external light trigger. Ruthenium cylinder and 
its tetrahedron conjugate were also shown to have potent cytotoxic capabilities when utilised 
as a photodynamic therapy agent, where the cylinder is delivered to genomic DNA and 
apoptosis is triggered by photocleavage caused by subsequent excitation with light. By utilising 
the difference in toxicity with and without tetrahedron, further research into widening the 
therapeutic window of the RuCy when being used as a PDT agent would be very interesting. 
The versatility of the cylinder was also demonstrated by the spatial recognition of a looped 
structure of RNA. The RNA, known as TAR, is found in the virus HIV-1 and binds to ADP-1 
protein to regulate transcription to facilitate viral capsid replication. The competitive binding 
of the iron, nickel and ruthenium cylinders was able to inhibit binding between TAR and ADP-
1 and thus had potential to become a new class of anti-viral agents. This is particularly exciting 
as the cylinder’s action in this chapter was not sequence specific, but more specific to the RNA 
structure. This makes it less susceptible to common virus adaptations to develop drug 
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resistance. There is a great deal of opportunity in research for the cylinders as a new class of 
anti-viral agents due to the large amount of discovered RNA secondary structures in nature.   
 
6.1.2 Future Work 
6.1.2.1 Chapter 2 
Following from chapter 2, it would be interesting to see the differences between the iron 
cylinder enantiomers in the 3WJ competition assays. From this thesis it has been seen that the 
M enantiomer is more effective at compressing the tetrahedron. Therefore its affinity to the 
synthetic 3WJ could also be different to the P enantiomer when competing with other DNA 
structures.  
Current collaborations are also currently working to establish whether the differences between 
the M and P enantiomers on the DNA tetrahedron can be seen by atomic force microscopy as 
previously seen with the racemic mixture by Prof. Shao Fengwei and Dr Liying Wang. 
6.1.2.2 Chapter 3 
The localisation of the tetrahedron and tetrahedron conjugate inside the cell remains a question. 
Whilst no significant co-localisation with the Hoechst nuclear stain and the Cy5 labelled 
tetrahedron was seen, another cell stain could be used to see whether any significant co-
localisation could be seen between the two which could confirm the cellular localisation of the 
complexes. This co-localisation could be quantified and any difference to localisation when 
cylinder is attached to the tetrahedron or not could be analysed.  
Furthermore, the integrity of the cylinder – tetrahedron conjugate whilst inside the cell still 
must be confirmed. This remains a challenging task, which one solution could be to furnish a 
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FRET pair between the cylinder and the tetrahedron and analyse the intensity whilst inside the 
cell. Unfortunately, creating a cylinder with a fluorescent tag remains a long term goal as 
synthesis often results in insoluble cylinders or cylinders with altered characteristics to the 
parent cylinder. An alternative proposition could be to use a fluorescent tag on the tetrahedron 
which is quenched upon cylinder binding. The intensity of this tag would increase on cylinder 
release and the integrity of the conjugate could be assessed in this fashion.   
6.1.2.3 Chapter 4  
Very interesting results involving the photocleavage capability of the ruthenium cylinder were 
observed in chapter 4. One further experiment which would shed light on whether the ruthenium 
cylinder is a good candidate for PDT would be to measure the amount of singlet oxygen created, 
when irradiated by light, with Raman spectroscopy.  
As seen in figure 4.17, potent cytotoxicity is observed by the ruthenium cylinder. As this was 
only initial testing, more rigorous experimentation is required to fully explore this, varying 
irradiation times and concentrations. It would also be interesting to combine an intercalator 
drug inside the tetrahedron with a view to releasing the drug on light excitation which would 
then trigger a cytotoxic response from that intercalator drug. Delivery by this method could 
increase specificity and decrease potential side effects as the tetrahedron could be light activated 
locally on a patient.  
6.1.2.4 Triggered release of an encapsulated cargo 
One of the aims of this thesis was to use supramolecular cylinders with DNA nanostructures to 
trigger the release of a therapeutic cargo. Two ways in which this could be achieved were 
highlighted in chapter 2 and chapter 4. In chapter 2, the iron cylinder was shown to compress 
the DNA tetrahedron into a smaller size, which would decrease the size of the internal cavity. 
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This in turn could cause the cavity to release a cargo which would now be too large to be 
accommodated by the cavity (Figure 6.1a).  
In chapter 4, the tetrahedron was shown to be photo cleaved apart by a ruthenium cylinder on 
excitation by light. This proposes that an internalised cargo could be released by ‘breaking the 
bars’ of the cage through photocleavage, opening up the central cavity (Figure 6.1b).  
 
 
 
For this triggered release to be possible, a cargo must first be internalised. Initial work was 
completed on one approach. This involved expressing hexa-histidine tagged EGFP (enhanced 
green fluorescent protein) from e.coli (Escherichia coli) bacteria. This protein was then attached 
to one of the tetrahedron oligonucleotide strands, following a protocol first reported by Shimada 
et al. in 2008.1 The coupling involves functionalising the oligonucleotide with Nitrilotriacetate 
(NTA). This was done by purchasing an oligo functionalised with a thiol group at the 5’ end 
+ + 
hv 
A 
B 
Figure 6.1 – A) Model diagram illustrating cargo released triggered by binding and 
subsequent compressing of a DNA tetrahedron by the iron cylinder. B) ‘Breaking the bars’ 
of a DNA tetrahedron on excitation by light. 
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(Eurofins). The oligo was then incubated with tris(2-carboxyethyl)phosphine (TCEP) for 2 
hours to reduce and activate the thiol group. Maleimido-C3-NTA (N-[5-(3′-
maleimidopropylamido)-1-carboxypentyl]iminodiacetic acid, disodium salt, monohydrate 
(Dojindo) was then added and incubated for 24 hours with shaking to furnish the NTA-
functionalised oligo. The remaining three oligos were then added to anneal the tetrahedron in 
the same manner as previously stated, still filtering with the 30k MWCO filter (Pierce) to 
remove excess NTA. Excess NiCl2 and His-EGFP were then added and incubated in the fridge 
overnight. To remove any unbound EGFP, the mixture was added to a Ni-NTA agarose mini 
column (Thermofisher). The resulting EGFP-tetrahedron was then be analysed on a 
fluorimeter (PTI MD-50-20). The overall coupling can be seen visually in Figure 6.2. 
 
 
 
+ 
Nitrilotriacetate 
tagged Strand 
NT
His-
tagged 
EGFP 
NiCl
2
 
Ni-NTA Linked conjugate 
EGFP 
Oligo 
Strand 
Figure 6.2 – Model diagram illustrating the coupling between His-tagged EGFP and 
a DNA oligonucleotide.  
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The orientation of the EGFP could be controlled by following the same method reported by 
Erben et al.2 By simply selecting the 5’ position by ordering the nucleotides corresponding to 
their helical turn per base (Figure 6.3). Through this, tetrahedra with both EGFP facing 
directly into the internal cavity and also one facing directly outside the cavity were 
synthesised but unfortunately never characterised fully.  
 
 
 
 
 
 
As further work, this protein internalisation needs further characterisation to fully confirm 
synthesis. Following from this, adding either the iron or ruthenium cylinders for each method 
of triggered delivery could be tested. Unfortunately in initial testing the blue light required 
for photocleavage proved to be able to bleach some of the fluorescence from the protein and 
the iron cylinder also quenched protein fluorescence when bound to the tetrahedron.  
Building on this protein encapsulation, alternative cargoes could be found to fully realise the 
potential for the cylinders releasing an internalised cargo from a DNA nanostructure.  
 
 
 
Figure 6.3 – Model diagram showing how protein attachment position can be 
manipulated by altering the sequence of the functionalised oligonucleotide. 
Taken from ref 2. 
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